PF-[ADDRESS_1121764] OF TABLET FORMULATION AND FOOD ON THE RELATIVE 
BIOAVAILABILITY OF PF -06821497  
 
 
 
Study  Intervention  Number:  PF-06821497  
Study  Intervention  Name:  [CONTACT_219912]:  CCI  
EudraCT Number:  NA 
ClinicalTrials.gov ID: NA 
Pediatric  Investigational  Plan  Number:  NA 
Protocol  Number:  C2321005  
Phase:  Phase  1 
Brief Title: A Phase 1, Single -dose, Relative Bioavailability  Study  to Investigate the 
Effect  of Tablet  Formulation  and Food  on PF-06821497  Pharmacokinetics  in Healthy 
Participants.  
 
 
This document  and accompanying  materials  contain  confidential  information  belonging  to [COMPANY_007].  Except  as 
otherwise agreed to in writing, by [CONTACT_22788], you agree to hold this 
information  in confidence  and not copy  or disclose  it to others  (except  where  required  by [CONTACT_61285]) or 
use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, [COMPANY_007] 
must be promptly notified.  

PF-[ADDRESS_1121765]  OF TABLES  ................................ ................................ ................................ .....................  8 
1. PROTOCOL  SUMMARY  ................................ ................................ ................................ ..... 9 
1.1. Synopsis  ................................ ................................ ................................ .....................  9 
1.2. Schema ................................ ................................ ................................ .....................  17 
1.3. Schedule  of Activities  ................................ ................................ ..............................  18 
2. INTRODUCTION  ................................ ................................ ................................ ................  23 
2.1. Study  Rationale  ................................ ................................ ................................ ........  23 
2.2. Background  ................................ ................................ ................................ ..............  23 
2.2.1.  Nonclinical Pharmacology  ................................ ................................ ..........  23 
2.2.2.  Nonclinical  Pharmacokinetics  and Metabolism  ................................ ..........  23 
2.2.3.  Nonclinical  Safety  ................................ ................................ .......................  24 
2.2.4.  Clinical  Overview  ................................ ................................ .......................  25 
2.2.5.  [IP_ADDRESS]  Safety  Overview  ................................ ................................ ..............  25 
2.2.6.  [IP_ADDRESS].  Summary  of PF-06821497  Pharmacokinetics  in Humans  .............  27 
2.3. Benefit/Risk Assessment  ................................ ................................ .........................  28 
2.3.1.  Risk Assessment  ................................ ................................ .........................  29 
3. OBJECTIVES  AND  ENDPOINTS  ................................ ................................ .....................  31 
4. STUDY  DESIGN  ................................ ................................ ................................ .................  31 
4.1. Overall  Design  ................................ ................................ ................................ .........  31 
4.2. Scientific Rationale for Study  Design  ................................ ................................ ..... 34 
4.2.1.  Assessment  of Safety  Data Before Administration of the High -fat 
Meal in Part 2 of the Study  ................................ ................................ ..............  35 
4.2.2.  Choice  of Contraception/Barrier Requirements  ................................ ..........  35 
4.2.3.  Collection  of Retained  Research  Samples  ................................ ...................  35 
4.3. Justification for Dose  ................................ ................................ ...............................  36 
4.4. End of Study  Definition  ................................ ................................ ...........................  37 
5. STUDY POPULATION  ................................ ................................ ................................ ...... 37 
5.1. Inclusion  Criteria  ................................ ................................ ................................ ..... 37 
5.2. Exclusion Criteria  ................................ ................................ ................................ .... 38 
5.3. Lifestyle  Considerations  ................................ ................................ ..........................  40 
5.3.1.  Contraception  ................................ ................................ ..............................  40 
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  4  
 5.3.2.  Meals and Dietary  Restrictions  ................................ ................................ .. 41 
5.3.3.  Caffeine,  Alcohol,  and Tobacco  ................................ ................................ . 42 
5.3.4.  Activity  ................................ ................................ ................................ ...... 42 
5.4. Screen  Failures  ................................ ................................ ................................ ........  42 
6. STUDY  INTERVENTION(S)  AND  CONCOMITANT  THERAPY  ................................ . 42 
6.1. Study  Intervention(s)  Administered  ................................ ................................ ........  43 
6.1.1.  Administration  ................................ ................................ ............................  43 
6.2. Preparation, Handling, Storage, and Accountability  ................................ ..............  45 
6.2.1.  Preparation  and Dispensing  ................................ ................................ ........  46 
6.3. Assignment to Study Intervention  ................................ ................................ ..........  46 
6.4. Blinding  ................................ ................................ ................................ ..................  46 
6.5. Study  Intervention  Compliance  ................................ ................................ ..............  46 
6.6. Dose  Modification  ................................ ................................ ................................ .. 46 
6.7. Continued  Access to  Study  Intervention After  the End  of the Study  .....................  47 
6.8. Treatment of Overdose  ................................ ................................ ...........................  47 
6.9. Prior  and Concomitant  Therapy  ................................ ................................ ..............  47 
6.9.1.  Rescue  Medicine  ................................ ................................ ........................  48 
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT  
DISCONTINUATION/WITHDRAWAL  ................................ ................................ ...........  48 
7.1. Discontinuation of Study  Intervention  ................................ ................................ .... 48 
7.1.1.  COVID -19 ................................ ................................ ................................ .. 49 
7.2. Participant Discontinuation/Withdrawal From the Study  ................................ ...... [ADDRESS_1121766] to Follow -up ................................ ................................ ................................ ... 50 
8. STUDY  ASSESSMENTS  AND  PROCEDURES  ................................ ..............................  50 
8.1. Administrative  Procedures  ................................ ................................ ......................  50 
8.2. Efficacy  Assessments  ................................ ................................ .............................  51 
8.3. Safety Assessments  ................................ ................................ ................................ . 51 
8.3.1.  Physical  Examinations  ................................ ................................ ...............  52 
8.3.2.  Vital  Signs  ................................ ................................ ................................ .. 52 
[IP_ADDRESS].  Blood Pressure and Pulse Rate ................................ .................  52 
[IP_ADDRESS].  Respi[INVESTIGATOR_82218] ................................ ................................ ....... 53 
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  5  
 CCI [IP_ADDRESS].  Temperature  ................................ ................................ ...............  53 
8.3.3.  Electrocardiograms  ................................ ................................ ......................  53 
8.3.4.  Clinical  Safety  Laboratory  Assessments  ................................ .....................  54 
8.3.5.  COVID -19 Specific  Assessments  ................................ ...............................  54 
8.3.6.  Pregnancy  Testing  ................................ ................................ .......................  54 
8.4. Adverse  Events, Serious  Adverse Events, and  Other  Safety  Reporting  ..................  55 
8.4.1.  Time Period and Frequency  for Collecting AE and SAE Information  ....... 55 
[IP_ADDRESS].  Reporting SAEs to [COMPANY_007] Safety  ................................ ...............  56 
[IP_ADDRESS].  Recording  Nonserious  AEs and SAEs  on the CRF ...................  56 
8.4.2.  Method  of Detecting  AEs and SAEs  ................................ ...........................  56 
8.4.3.  Follow -Up of AEs and SAEs  ................................ ................................ ...... 56 
8.4.4.  Regulatory  Reporting Requirements for SAEs  ................................ ...........  57 
8.4.5.  Environmental Exposure, Exposure During Pregnancy  or 
Breastfeeding, and Occupational Exposure  ................................ .....................  57 
[IP_ADDRESS].  Exposure During Pregnancy  ................................ ......................  57 
[IP_ADDRESS].  Exposure  During  Breastfeeding  ................................ .................  59 
[IP_ADDRESS].  Occupational Exposure  ................................ ..............................  59 
8.4.6.  Cardiovascular  and Death  Events  ................................ ................................  60 
8.4.7.  Disease -Related  Events  and/or  Disease -Related  Outcomes  Not 
Qualifying  as AEs or SAEs  ................................ ................................ ..............  [ADDRESS_1121767]  ................................ .............................  60 
[IP_ADDRESS].  Lack  of Efficacy  ................................ ................................ .........  60 
8.4.9.  Medical  Device  Deficiencies  ................................ ................................ ...... 60 
8.4.10.  Medication  Errors  ................................ ................................ ......................  60 
8.5. Pharmacokinetics  ................................ ................................ ................................ ..... 61 
 
 
 
 
 
 
 
8.8. Immunogenicity  Assessments  ................................ ................................ ................  63 
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  6  
 8.9. Health  Economics  ................................ ................................ ................................ ... 63 
9. STATISTICAL  CONSIDERATIONS  ................................ ................................ ................  63 
9.1. Statistical Hypotheses  ................................ ................................ .............................  63 
9.2. Analysis  Sets ................................ ................................ ................................ ...........  63 
9.3. Statistical Analyses  ................................ ................................ ................................ . 64 
9.3.1.  Pharmacokinetic Analysis  ................................ ................................ ..........  64 
[IP_ADDRESS].  Derivation of Pharmacokinetic Parameters  ..............................  64 
9.3.2.  Statistical  Methods  for PK Data ................................ ................................ . 65 
9.3.3.  Other  Safety  Analyses  ................................ ................................ ................  65 
CCI  
9.4. Interim  Analyses  ................................ ................................ ................................ ..... 66 
9.5. Sample Size Determination  ................................ ................................ ....................  66 
10. SUPPORTING   DOCUMENTATION   AND   OPERATIONAL  
CONSIDERATIONS  ................................ ................................ ................................ ..........  68 
10.1. Appendix  1: Regulatory,  Ethical, and  Study  Oversight Considerations  ...............  68 
10.1.1.  Regulatory  and Ethical Considerations  ................................ ....................  68 
[IP_ADDRESS].  Reporting of Safety Issues and Serious Breaches of the  
Protocol  or ICH GCP  ................................ ................................ ........  68 
10.1.2.  Financial  Disclosure  ................................ ................................ .................  69 
10.1.3.  Informed  Consent  Process  ................................ ................................ ....... 69 
10.1.4.  Data  Protection  ................................ ................................ .........................  70 
10.1.5.  Committees  Structure  ................................ ................................ ...............  70 
[IP_ADDRESS].  Data  Monitoring  Committee  ................................ ...................  70 
10.1.6.  Dissemination  of Clinical Study  Data ................................ ......................  70 
10.1.7.  Data  Quality  Assurance  ................................ ................................ ............  71 
10.1.8.  Source Documents  ................................ ................................ ...................  73 
10.1.9.  Study  and Site Start and Closure  ................................ ..............................  73 
10.1.10.  Publication Policy  ................................ ................................ ..................  74 
10.1.11.  Sponsor’s Medically  Qualified Individual  ................................ .............  75 
10.2. Appendix 2: Clinical Laboratory  Tests  ................................ ................................  76 
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording,  
Evaluating,  Follow -Up, and Reporting  ................................ ................................ ..... 78 
10.3.1.  Definition  of AE ................................ ................................ .......................  78 
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  7  
 10.3.2.  Definition  of an SAE ................................ ................................ ................  79 
10.3.3.  Recording/Reporting  and Follow -Up of AEs and/or  SAEs During  
the Active Collection Period  ................................ ................................ ...........  80 
10.3.4.  Reporting of SAEs  ................................ ................................ ...................  84 
10.4. Appendix  4: Contraceptive  and Barrier  Guidance  ................................ ................  85 
10.4.1.  Male  Participant  Reproductive  Inclusion  Criteria  ................................ .... 85 
10.4.2.  Female Participant Reproductive Inclusion Criteria  ................................  85 
10.4.3.  Woman  of Childbearing  Potential  ................................ ............................  86 
10.4.4.  Contraception  Methods  ................................ ................................ ............  87 
CCI  
10.6. Appendix  6: Liver  Safety:  Suggested  Actions  and Follow -Up Assessments  ....... 90 
10.7. Appendix 7: Kidney  Safety: Monitoring Guidelines  ................................ ............  92 
10.7.1.  Laboratory  Assessment of Change in Kidney  Function and 
Detection of Kidney Injury  ................................ ................................ .............  92 
10.7.2.  Age-Specific  Kidney  Function  Calculation  Recommendations  ...............  92 
[IP_ADDRESS].  Adults  (18 Years  and Above) —2021 CKD -EPI 
[INVESTIGATOR_185560]  ................................ ................................ ..........................  92 
10.7.3.  Adverse  Event  Grading  for Kidney  Safety  Laboratory  
Abnormalities  ................................ ................................ ................................ .. 92 
10.8. Appendix  8: ECG  Findings  of Potential  Clinical  Concern  ................................ ... 93 
10.9. Appendix 9: Abbreviations  ................................ ................................ ...................  [ADDRESS_1121768] OF TABLES  
Table  1. Treatment Schedule ................................ ................................ ..................  33 
Table  2. Summary  of PF -06821497 Formulations  ................................ .................  43 
Table  3. Plasma  PF-06821497  PK Parameters  Definitions  ................................ .... 64 
Table  4. Expected  Widths  of the  90% CIs  for Different  Possible Estimated  
Effects  and Parameters  of Interest  for Part 1 Study  ................................ . 66 
Table  5. Expected  Widths  of the 90% CIs  for Different  Possible Estimated  
Effects  and Parameters  of Interest  for Part 2 Study  ................................ . 67 
Table  6. Protocol -Required  Safety  Laboratory  Assessments  ................................ . 76 
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  9  
 1. PROTOCOL  SUMMARY  
1.1. Synopsis  
Protocol  Title:  A Phase  1, Randomized,  Open -label,  3-period,  crossover,  single -dose,  2-part 
study in healthy participants to investigate the effect of tablet formulation and food on the 
bioavailability of PF -06821497  
Brief  Title:  A Phase  1, Single -dose,  Relative  Bioavaialbility  Study  to Investigate  the Effect 
of Tablet Formulation  and Food  on PF -06821497 Pharmacokinetics  in Healthy  Participants  
Regulatory  Agency  Identification  Number(s):  
 
US IND Number:  CCI  
EudraCT  Number:  NA 
ClinicalTrials.gov  ID: NA 
Pediatric  Investigational  Plan  Number:  NA 
Protocol  Number:  C2321005  
Phase:  Phase 1 
 
Rationale:  
The purpose of the study  is to investigate the relative bioavailability  of tablet formulations of 
PF-[ADDRESS_1121769]  of food on a PF-06821497  CCI  tablet  formulation 
(Formulation 2). The data generated from this study  will be used to support the pi[INVESTIGATOR_811016], to inform dose administration instructions for PF -[ADDRESS_1121770] to 
dosing with or without food, and to enable the establishment of the API [INVESTIGATOR_811017].  
Objectives  and Endpoints:  
 
Objectives  Endpoints  
Primary:  Primary:  
• To estimate the bioavailability of a single  C  mg dose of PF - 
06821497  CC tablet  formulation  (Formulation  2) relative  to a 
single  C  mg dose of PF -06821497  CCI tablet formulation 
(Formulation 1) under fasted conditions in adult healthy 
participants  • Plasma AUC inf and C max for PF -06821497. 
(AUC last will be used as the primary  estimate  if 
AUC inf cannot be reliably estimated).  
Secondary:  Secondary:  
• To estimate the bioavailability of a single  C  mg dose of PF - 
06821497  CC tablet (larger API [INVESTIGATOR_811018]) formulation 
(Formulation 3) relative to a single  C  mg dose of PF - 
06821497  CC tablet  (Formulation  2) and a single  C  mg dose 
of the PF -06821497  CCI tablet formulation (Formulation 1)  
under  fasted  conditions  in adult  healthy  participants  •  Plasma AUC inf and C max for PF -06821497 for 
CC tablet  (larger  API [INVESTIGATOR_811019])  (Formulation 
3) relative to  CC (Formulation 2) and  CCI 
tablet  (Formulation  1) formulations.  (AUC last will 
be used as the primary estimate if AUC inf cannot 
be reliably estimated).  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  10  
 C  
Objectives  Endpoints  
•  To estimate  the effect  of a high-fat, high -calorie  meal  on the 
bioavailability  of a single  CCI mg dose of the PF-06821497 
CC tablet formulation (Formulation 2) relative to fasted 
conditions in adult healthy participants  
•  To estimate the effect of a low -fat, low -calorie meal on the 
bioavailability  of a single  CCI mg dose of the PF-06821497 
CC tablet formulation (Formulation 2) relative to fasted 
conditions in adult healthy participants  • Plasma AUC inf and C max for PF -06821497 
under fed (high -fat, high -calorie meal) 
conditions relative to fasting conditions. 
(AUC last will be used as the primary  estimate  if 
AUC inf cannot be reliably estimated).  
• Plasma AUC inf and C max for PF -06821497 under 
fed (low-fat, low-calorie  meal)  conditions  relative 
to fasting  conditions.  (AUC last will be used as the 
primary estimate if AUC inf cannot be reliably 
estimated).  
• To evaluate  the safety  and tolerability  of PF-06821497  when 
administered as a tablet formulation to healthy participants  • Assessment of TEAEs, clinical laboratory 
abnormalities,  vital signs,  physical  examinations, 
and 12 -lead ECGs.  
Overall  Design:  
This is a Phase  1, randomized,  open -label,  3-period,  single -dose 2-part study  in healthy  adult 
participants to investigate the effect of tablet formulation and food on the bioavailability of 
PF-06821497.  
Intervention  Groups  and Duration: 
Part 1 (rBA):  
Sequence  Period  1 Washout:  at 
least  C days 
between  PF- 
06821497  
doses  Period  2 Washout: at 
least  C days 
between PF - 
06821497  doses  Period  3 
1 (6 Participants)  A B C 
2 (6 Participants)  B A C 
Treatment  A – CCI  formulation  (Formulation  1) 
Treatment B – CC  formulation (Formulation 2) 
Treatment C – CC  formulation (Formulation 3)  
 
Part  2 (Food  effect):  C fasted;  
CC fasted;  
C ; larger  particle  size)  fasted  ; 
C 
 
 
 
 
 
Treatment  D – CC  formulation  ((Formulation  2) C fasted;  
Treatment  E – CC formulation  (Formulation  2) 
Treatment  F – CC formulation  (Formulation  2) CC fed: Low-fat meal;  
C fed: High -fat meal 
C 
There  will be a minimum  of CCI  washout period between successive PF -06821497 doses.  
F 
Period  3 
 Washout: at 
least  C days 
between PF - 
06821497  doses  
Period  2 
E 
Washout:  at 
least  C days 
between  PF- 
06821497  
doses  
D 
 1 (6 Participants)  
Period  [ADDRESS_1121771] dose of the  
IP and if all entry criteria are fulfilled, the participants will report to the PCRU on the day 
prior to Day 1 dosing (Day -1) of each period. For Treatments A, B, and C, following an 
overnight fast of at least [ADDRESS_1121772] administration of study intervention to capture any potential AEs and confirm 
appropriate contraceptive usage.  
Number of Participants:  
Approximately [ADDRESS_1121773] to the primary PK objective(s), additional participants can be enrolled at the 
discretion of the investigator upon consultation with the sponsor.  
Note:  "Enrolled"  means  a participant's,  or their legally  authorized  representative’s,  agreement 
to participate in a clinical study following completion of the informed consent process and 
assignment to study intervention. A participant will be considered enrolled if the informed 
consent is not withdrawn prior to participating in any study activity. Potential participants  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  12  
 who are screened for the purpose of determining eligibility for the study, but do not 
participate  in the study,  are not considered  enrolled,  unless  otherwise  specified  by [CONTACT_12695].  
Study Population:  
Inclusion  and exclusion criteria  are listed below:  
Inclusion  Criteria  
Participants  must  meet  the following  inclusion  criteria  to be eligible  for enrollment  into the 
study:  
1. Participants  ≥18 years  of age, inclusive,  at screening.  
2. Male and female participants who are overtly healthy as determined by [CONTACT_811033],  physical  examination,  laboratory  tests,  vital 
signs and 12 -lead ECGs.  
3. BMI  of ≥17.5 kg/m2; and a total body  weight >50 kg  (110 lb) 
4. Evidence  of a personally  signed  and dated  ICD indicating  that the participant  has 
been informed of all pertinent aspects of the study.  
5. Participants  who are willing  and able to comply  with all scheduled  visits,  treatment 
plan, laboratory tests, lifestyle considerations, and other study procedures.  
Exclusion  Criteria  
Participants  with any of the following  characteristics/conditions  will be excluded:  
1. Evidence or history of clinically significant hematological, renal, endocrine, 
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or 
allergic disease (including drug allergies, but excluding untreated, asymptomatic, 
seasonal  allergies  at the time of dosing)  or prior  allergic  reaction  to any component  of 
PF-06821497.  
• Any condition possibly affecting drug absorption (eg, gastrectomy, 
cholecystectomy,  prior  bariatric  surgery,  ileal resection,  inflammatory 
gastrointestinal  disease,  chronic  diarrhea,  known  diverticular  disease).  
• History  of HIV infection,  hepatitis  B, or hepatitis  C; positive  testing  for HIV, 
HBsAg, HBcAB or HCVAb. Hepatitis B vaccination is allowed.  
• Chronic  liver diseases  including  alcoholic  liver disease,  viral hepatitis, 
primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  13  
 hepatitis,  Wilson’s  disease,  hemochromatosis,  alpha -1 antitrypsin  deficiency, 
human immunodeficiency virus, or other chronic liver disease.  
2. Other medical or psychiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory abnormality or other conditions or 
situations related to COVID -19 pandemic  that may increase the risk of study 
participation  or, in the investigator’s  judgment,  make  the participant  inappropriate  for 
the study.  
3. Use of prescription  or nonprescription  drugs  and dietary  and herbal  supplements 
within  7 days or 5 half-lives  (whichever  is longer)  prior  to the first dose of study 
intervention.  
• Current use or anticipated need for food or drugs that are known strong 
inducers or inhibitors of CYP3A4/5, including their administration within 10 
days or 5 half-lives  of the strong  inducer  or inhibitor  of CYP3A4/5,  whichever 
is longer prior to first dose of investigational product  
o Strong CYP3A4/5 inhibitors: eg, grapefruit juice or 
grapefruit/grapefruit related citrus fruits (eg, Seville oranges, 
pomelos), ketoconazole, miconazole, itraconazole, voriconazole, 
posaconazole, clarithromycin, telithromycin, indinavir, saquinavir, 
ritonavir,  nelfinavir,  amprenavir,  fosamprenavir  nefazodone,  lopi[INVESTIGATOR_054], 
troleandomycin, mibefradil, and conivaptan.  
 
o Strong  CYP3A4/5  inducers:  eg, phenobarbital,  rifampin,  phenytoin, 
carbamazepi[INVESTIGATOR_050], rifabutin, rifapentin, clevidipi[INVESTIGATOR_050], St. John’s Wort.  
 
• Time  dependent  inhibitors  of CYP3A4/[ADDRESS_1121774]  21 days prior  to the 
treatment  
o Time  dependent  inhibitors  of CYP3A4/5:  azamulin,  troleandomycin, 
verapamil, boceprevir, nelfinavir, and telapravir  
4. Previous  administration  with an investigational  product  (drug  or vaccine)  within  
30 days (or as determined  by [CONTACT_219873])  or [ADDRESS_1121775] 
dose of study intervention used in this study (whichever is longer).  
5. A positive urine drug test. 
6. Screening  supi[INVESTIGATOR_145972] ≥140  mm Hg (systolic)  or ≥90 mm Hg (diastolic),  following  at 
least [ADDRESS_1121776]. If BP is ≥140 mm Hg (systolic) or ≥90 mm Hg 
(diastolic), the BP should be repeated 2 more times and the average of the 3 BP 
values should be used to determine the participant’s eligibility.  
7. Standard  [ADDRESS_1121777], if deemed necessary:  
• AST or ALT level > ULN;  
• Total  bilirubin level >1 × ULN;  
• PT, international  normalized  ratio (INR)  and aPTT  outside  of normal  limits  at 
baseline  
• eGFR  <60 mL/min/1.73  m2 based  on the CKD -EPI [INVESTIGATOR_10908];  
• Absolute neutrophil count <0.8  × LLN.  
9. History of alcohol abuse or binge drinking [more than 4 drinks on any day or 14 
drinks per week where 1 drink is defined as the alcoholic beverage containing 
approximately  (1 unit = 8 ounces  (240 mL) beer,  1 ounce  (30 mL) of 40% spi[INVESTIGATOR_811020] 3 
ounces (90 mL) of wine)] in the last [ADDRESS_1121778] (ie, active  smokers  and those  who currently  use nicotine 
containing products are excluded from participation in this study).  
11. Pregnant female participants; breastfeeding female participants; fertile male 
participants and female participants of childbearing potential who are unwilling or 
unable  to use [ADDRESS_1121779].  
12. Blood  donation  (excluding  plasma  donations)  of approximately  1 pi[INVESTIGATOR_11731] (500 mL) or 
more within [ADDRESS_1121780] of the study and their family 
members.  
Study Arms and Duration:  
Each participant will be screened within [ADDRESS_1121781] dose of the IP and if all 
entry  criteria  are fulfilled,  the participants  will report  to the PCRU  on the day prior  to Day 1 
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  15  
 dosing  (Day  -1) of each period.  A safety  follow -up call will be made  to participants  28 to 35 
days from administration of the final dose of study intervention.  
In each part of the study, each enrolled participant will participate in 3 study periods to 
receive  3 different  treatments  according  to the sequence  determined  by [CONTACT_811034] C- 
day washouts between PF -06821497 administration:  
Part  1: 
• Treatment  A – CCI  formulation  (Formulation  1) CCI  fasted;  
• Treatment  B – CCI  formulation  (Formulation  2) CCI  fasted;  
• Treatment C – CCI  formulation (Formulation 3) CCI ; larger  API 
[INVESTIGATOR_811018]) fasted;  
Part  2: 
• Treatment  D – CCI  formulation  (Formulation  2) CCI  fasted;  
• Treatment E – CCI  formulation (Formulation 2) CCI  fed: Low-fat 
meal;  
• Treatment F – CCI  formulation (Formulation 2) CCI  fed: High -fat 
meal;  
Statistical  Methods:  
Part  1: 
Natural log transformed AUC inf (if data permit), AUC last and C max will be analyzed using a 
mixed effects model with sequence, period and treatment as fixed effects and participant 
within sequence as a random effect.  Estimates of the adjusted mean differences (Test - 
Reference) and corresponding 90% confidence intervals will be obtained from the model. 
The adjusted mean differences and 90% confidence intervals for the differences will be 
exponentiated  to provide  estimates  of the ratio of adjusted  geometric  means  (Test/Reference) 
and 90% confidence intervals for the ratios. Treatment A (CCI  formulation (Formulation 1) 
CCI  fasted) will be the Reference treatment and Treatment B (CCI  
formulation (Formulation 2) CCI  fasted) will be the Test treatment.  
Natural log transformed AUC inf (if data permit), AUC last and C max will be analyzed using a 
mixed effects model with sequence and treatment as fixed effects and participant within 
sequence as a random effect.  Estimates of the adjusted mean differences (Test -Reference) 
and corresponding  90% confidence  intervals  will be obtained  from  the model.  The adjusted 
mean differences and 90% confidence intervals for the differences will be exponentiated to 
provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% 
confidence intervals for the ratios. Treatment A (CCI  formulation (Formulation 1)  CCI  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  16  
 CCI  fasted) will be the Reference treatment and Treatment C (CCI  formulation 
(Formulation 3) CCI ; larger API [INVESTIGATOR_811018]) fasted) will be the Test 
treatment.  For the second  comparison,  Treatment  B (CCI  formulation  (Formulation  2) CCI 
will be the Reference  treatment  and Treatment  C (CCI formulation  
(Formulation 3) CCI ; larger  API [INVESTIGATOR_811019])  fasted)  will be the Test 
treatment.  
Part  2: 
Natural  log transformed  AUC inf (if data permit),  AUC last and Cmax will be analyzed  using  a 
mixed effects model with treatment as a fixed effect and participant as a random effect.  
Estimates of the adjusted mean differences (Test -Reference) and corresponding 90% 
confidence intervals will be obtained from the model.  The adjusted mean differences and 
90% confidence  intervals  for the differences  will be exponentiated  to provide  estimates  of the 
ratio of adjusted geometric means (Test/Reference) and 90% confidence intervals for the 
ratios. Treatment D (CCI  formulation (Formulation 2) CCI  fasted) will be 
the Reference treatment and Treatments E and F (CCI  formulation (Formulation 2) 1250 mg 
CCI  fed: low -fat meal and CCI  formulation (Formulation 2)CCI   
fed: high -fat meal) will be the Test treatments.  
 
Pharmacokinetics  Analysis  
The PK concentration  population  is defined  as all participants  randomized  and treated  who 
have at least [ADDRESS_1121782]  noncompartmental  methods 
of analysis. Actual PK sampling times will be used in the derivation of PF -06821497 PK 
parameters when available, otherwise nominal times will be used. The PF -06821497 plasma 
PK parameters will be summarized descriptively by [CONTACT_75891]. Plasma concentrations will 
be listed and summarized descriptively by [CONTACT_75891], and nominal PK sampling time.  
Individual participant and summary  profiles (mean and median plots) of the plasma 
concentration  time data will be plotted  using  actual  and nominal  times,  respectively.  
Safety Analysis  
AEs,  ECGs,  BP, PR, RR, and safety  laboratory  data will be reviewed  and summarized  on an 
ongoing  basis  during  the study  to evaluate  the safety  of participants.  Any clinical  laboratory, 
ECG, BP, RR, and PR abnormalities of potential clinical concern will be described. Safety 
data will be presented in tabular and/or graphical format and summarized descriptively, 
where appropriate.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  17  
 Ethical Considerations:  
PF-06821497  will not provide  any clinical  benefit  to healthy  participants  in this study.  This 
study is designed primarily to further the understanding of human PK, metabolism, and 
elimination of PF -06821497. Participants will be expected to commit time and may 
experience some discomfort while undergoing study assessments.  
1.2. Schema  
Not applicable.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  18  
  
1.3. Schedule of Activities  
The SoA table provides an overview of the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND  
PROCEDURES  section  of the protocol  for detailed  information  on each procedure  and assessment  required  for compliance  with the 
protocol.  
The investigator  may schedule  visits  (unplanned  visits)  in addition  to those  listed  in the SoA table,  in order  to conduct  evaluations  or 
assessments required to protect the well -being of the participant.  
 
Visit Identifier 
Abbreviations  used 
in this table  may be 
found in  
Appendix 9.  
Days  Relative  to 
Day 1  
 
 
 
 
 
Hours  After  Dose  
 
Informed consent  
 
 
CRU  confinement  
 
 
 
 
 
 
Inclusion/exclusion 
criteria 
Medical/medicatio  
n history  Screening  
 
 
 
 
Day -28 
to 
Day -2 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
X 
X  
 
 
 
 
Day 
-1 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
X  
 
 
 
 
 
 
 
 
 
 
 
Pre-dose  0 Period  1 to Period  3 
 
 
 
 
Day 1 
 
 
 
 
 
 
CCI  
 
 
 
CCI 
 
 
 
 
 
 
 
 
 
 
C F/U 
 
 
 
 
28- 
35 
Day 
s Early 
Termination/ 
Discontinuation  Notes  
 
 
 
 
• Screening  will be performed  within  [ADDRESS_1121783] dose of PF -06821497.  
• Day -1 is applicable  for each check -in to the PCRU, 
unless particularly specified.  
• Follow -up contact  [CONTACT_811035] 28 to 35 days from administration of the 
final dose of study intervention  
 
 
• Informed  consent  should  be obtained  prior  to 
undergoing any study -specific procedures  
• See Section  10.1.3  for additional information.  
• Participants will be admitted to the PCRU on Day -[ADDRESS_1121784] 
and discharged on Day  Cof Period 3.  
• Inclusion/exclusion criteria will be reviewed at 
Screening  and at the Day -1 check -in for Period  1. 
• Medical history will include a history of prior illegal 
drug,  alcohol,  and tobacco  use and will be recorded  at 
Screening and updated on Period 1 Day -1. 
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  19  
  
Visit Identifier 
Abbreviations  used 
in this table  may be 
found in  
Appendix  9. Screening  Period  1 to Period  3 F/U Early 
Termination/ 
Discontinuation  Notes  
Days  Relative  to 
Day 1  Day -28 
to 
Day -2 Day 
-1 Day 1 Day 
2 Day 
3 28- 
35 
Day 
s  • Screening  will be performed  within  [ADDRESS_1121785] dose of PF -06821497.  
• Day -1 is applicable  for each check -in to the PCRU, 
unless particularly specified.  
• Follow -up contact  [CONTACT_811035] 28 to 35 days from administration of the 
final dose of study intervention  
Hours  After  Dose    Pre-dose 0 CC I        
             
Physical exam  X X                X • A completed  physical  examination  will be performed  by 
[CONTACT_811036] 1 Day -1 only (height and weight must be 
obtained at Screening to obtain BMI for eligibility 
criteria). Additional physical examination may be 
performed at other designated time points at the  
discretion of the investigator.  
PT, PTT,  INR X X              X  X  
Safety laboratory  X X              X  X • Safety laboratory assessments will be performed at 
Screening,  prior  to dosing  in each treatment  period  (can 
be Day -1 or pre -dose on Day 1 at discretion of 
investigator), and prior to each discharge from the  
PCRU  (could  be Day Cin each period  or only at Day C 
of Period 3 at discretion of investigator), and prior to 
early termination/discontinuation if applicable. All the  
safety  laboratory  samples  must  be collected  following  at 
least a [ADDRESS_1121786]. Additional safety laboratory 
assessments may be performed at any time at the 
discretion of the investigator (see Appendix 2 ) 
Demography  X                  • Demographics will include participant race, ethnicity, 
age, sex, height,  and weight  during  the Screening  visit.  
Pregnancy test 
(WOCBP  only)  X X              X  X • For Day Cit is only applicable  for Period  3 (See 
Section 8.3.6 ). 
Contraception 
check  X X               X X • Contraception  check  will be performed  according  to the 
conditions  described  in Section  5.3.1  
FSH X                  • For postmenopausal  (amenorrheic  for at least 12 
consecutive months) female participants only  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  20  
  
Visit Identifier 
Abbreviations  used 
in this table  may be 
found in  
Appendix  9. Screening  Period  1 to Period  3 F/U Early 
Termination/ 
Discontinuation  Notes  
Days  Relative  to 
Day 1  Day -28 
to 
Day -2 Day 
-1 Day 1 CCI 28- 
35 
Day 
s  • Screening  will be performed  within  [ADDRESS_1121787] dose of PF -06821497.  
• Day -1 is applicable for each check -in to the  
PCRU, unless particularly specified.  
• Follow -up contact [CONTACT_811037] 28 to 35 days from administration of 
the final dose of study intervention      
  
Hours  After  Dose    Pre-dose 0 CC I        
              
Urine drug 
screening/Urine 
cotinine/Alcohol 
breath test  X X       
 
 
 
 
C 
 
 
 
 
 
 
 
 
 
C            • Urine  drug and urine  cotinine  (mandatory)  and alcohol 
breath test (at discretion of investigator) will be 
performed  at Screening,  on Period  1 Day -1, and upon 
PCRU check -in on Day -1 of each subsequent period. 
These tests may be performed at any other time at the  
discretion of the investigator.  
12-Lead  ECG  X  X                X • Single [ADDRESS_1121788] in 
a supi[INVESTIGATOR_811021]. Additional ECGs may be taken at 
any time at the discretion of the investigator.  
• Single  12-lead ECG  monitoring  will be done  pre-dose of 
Day 1 of each treatment period.  
• Chour post-dose ECG  readings  are applicable  only for 
Periods 2 and 3 in Part 2. Day  Cmeasurements are for  
Period 3  only.   
Vital signs 
(BP/PR/RR  and 
temperature)  X  X                X • Single supi[INVESTIGATOR_30991], RR and PR will be performed 
following at least a [ADDRESS_1121789] in a supi[INVESTIGATOR_2547], at 
specified  time point.  BP, RR and PR assessments  will be 
performed after collection of ECGs and prior to 
collection of blood draws if scheduled at the same time.  
• Vital  sign measurements  will be done  pre-dose of Day 1 
of each treatment period.  
• Chour post-dose vital sign measurements  are applicable 
only for Periods 2 and 3 in Part 2. Day  Cmeasurements 
are for Period 3 only.   
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  21  
  
Visit Identifier 
Abbreviations  used 
in this table  may be 
found in  
Appendix 9.  
Days  Relative  to 
Day 1  
 
 
 
 
 
Hours  After  Dose  Screening  
 
 
 
 
Day -28 
to 
Day -2  
 
 
 
 
Day 
-1  
 
 
 
 
 
 
 
 
 
 
 
Pre-dose  0 Period  1 to Period  3 
 
 
 
 
Day 1 
 
 
 
 
 
 
CCI  
 
 
 
CCI F/U 
 
 
 
 
28- 
35 
Day 
s Early 
Termination/ 
Discontinuation  Notes  
 
 
 
 
• Screening  will be performed  within  [ADDRESS_1121790] dose of PF -06821497.  
• Day -1 is applicable  for each check -in to the PCRU, 
unless particularly specified.  
• Follow -up contact  [CONTACT_811035] 28 to 35 days from administration of the 
final dose of study intervention  
 
HIV, HBsAg,  X 
HBcAb, HCVAb  
COVID -19 related  X 
measures  
COVID -19 testing  X 
 
PF-06821497  
dosing  
 
 
 
Pharmacokinetic 
blood  sampling  for 
PF-06821497   
X 
X 
 
X 
 
 
 
X CCI  
 
• The measures  will be according  to PCRU  procedures.  
 
• The testing  for COVID -19 will be performed  per PCRU 
procedures or by [CONTACT_079].  
• PF-06821497  will be administered  orally  on Day 1 after 
overnight fasting until the start of study procedures for 
each treatment period. PF -06821497 will be 
administered orally and in fasted or fed state according 
to the conditions described in Protocol Section 5.3.2 . 
X • Blood  samples  (~2 mL) for PK analysis  of PF-06821497 
will be taken at predose (within approximately 1 hour 
prior to PF -06821497 dosing), and at the specified 
timepoints post dose. If ECG and BP/PR assessments  
are scheduled at the same nominal time point as a PK 
sample, PK samples should be collected after  
completion  of these  assessments.  A 10% time window  is 
allowable  for samples  collected  upto CCI . ≤ 1hour  is 
allowed  for samples  collected  at more  than CCI   
CCI 
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  22  
  
 
CCI 
C 
C 
 •See Section  8.4.3  for follow -up AE and SAE 
assessments.  
X 
 → 
 → 
 X 
 Serious and 
nonserious  AE 
monitoring  
•CRU discharge will be applicable for discharge day 
from the PCRU (could be Day C in each period or only 
at Day C of Period 3 at discretion of investigator, and 
prior  to early  termination/discontinuation  if applicable).  
CRU  discharge  
0 
 Pre-dose 
 Hours  After  Dose  
•Screening  will be performed  within  [ADDRESS_1121791] dose of PF -06821497.  
•Day -1 is applicable  for each check -in to the PCRU, 
unless particularly specified.  
•Follow -up contact  [CONTACT_811035] 28 to 35 days from administration of the 
final dose of study intervention  
28- 
35 
Day 
s 
CCI 
 Day 1 
 Day 
-1 
Day -28 
to 
Day -2 
Days  Relative  to 
Day 1  
Notes  
 Early 
Termination/ 
Discontinuation  
F/U 
 Period  [ADDRESS_1121792]  of food on a PF-06821497  CCI  tablet  formulation 
(Formulation 2). The data generated from this study  will be used to support the pi[INVESTIGATOR_811016], to inform dose administration instructions for PF -[ADDRESS_1121793]  in the clinic.  In oral repeat  dose toxicity  studies  in mice  and 
dogs, the systemic exposure of PF -06821497 generally CCI  in a CCI    
CCI  up to CCI kg/kg/day  (CCI mg/kg/dose  BID)  with no consistent  sex-related  differences  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  24  
 
CCI 
CCI 
of CCI 
CCI 
CCI 
CCI 
CCI 
CCI 
CCI 
CCI 
CCI 
CCI 
CCI 
CCI 
CCI 
CCI CCI CCI observed.  CCI accumulation  was observed  over the dosing  period.  PF-06821497  is 
a  of the   ; however,  nonclinical  in vivo PK results  suggested  a 
impact of  on intestinal absorption.  
PF-[ADDRESS_1121794] with blood to 
plasma ratios of CCI . Brain penetration of PF -06821497 was CCI  in mice, with 
unbound brain to plasma AUC ratios of  . PF-06821497 distributed into human 
hepatocytes by [CONTACT_811038].  
Preliminary in vitro metabolism evaluation of PF -06821497 showed similar metabolite 
profiles across species with no evidence of human specific metabolites. PF -06821497 was 
primarily metabolized by [CONTACT_811039]-CYP  mediated 
metabolism. CYP -mediated metabolism accounted for CCI  of the hepatic metabolism with  
and the predominant  CYP  isoforms,  whereas  
n -mediated  metabolism (CCI  was due, in part, to  CCI  
 
PF-[ADDRESS_1121795] (mucosal atrophy, congestion and erosion), hemato -lymphopoietic 
system (decreased cellularity in the bone marrow, myeloid and erythroid toxicity, decreased 
lymphocyte cellularity in the lymphoid organs), and male reproductive organs (seminiferous 
tubule degeneration and reduced sperm in epi[INVESTIGATOR_4046]). Partial to complete reversibility of 
target organ toxicities was established following a 1 -month non -dosing period.  
PF-06821497  was assessed  in a series  of exploratory  genetic  toxicity  studies  consisting  of the 
bacterial mutagenicity, in vitro cytogenetic (micronucleus in human lymphoblastoid TK6 
cells), a GLP bacterial mutagenicity assay, and a GLP in vivo mouse micronucleus assays.  CCI 
PF-[ADDRESS_1121796]  phototoxicity  potential  based  on its molar  extinction  coefficients.  In 
an investigative study of liver fibrosis in male mice, PF -06821497 did not increase or 
mitigate CCl4 -induced liver toxicity.  
Additional  information  of the nonclinical  safety  of PF-06821497  is available  in the current 
IB. 
2.2.4.  Clinical Overview  
PF-06821497 is currently being evaluated in an ongoing FIP open -label, multi -center, dose 
escalation and expanded cohort Phase 1 study (C2321001) to investigate the safety, 
tolerability, PK, PD, and preliminary efficacy of PF -06821497 as a single agent and in 
combination with SOC (Carboplatin or Cisplatin with etoposide for SCLC and enzalutamide 
for mCRPC)  to patients with SCLC, mCRPC, and FL. The study is comprised of 2 parts: 
Part 1 testing PF -06821497 monotherapy in 3 arms (Part 1A, 1B, 1C) and Part 2 testing 
combination therapy in 3 parts (Part 2A, 2B, 2C). For Part 2, PF -06821497 in combination 
with SOC will be evaluated in dose escalation (Part 2A) in patients with SCLC and mCRPC 
and then the combination regimen will be evaluated in a randomized dose expansion in 
patients  with mCRPC  (Part  2B). Alternative  doses  of PF-06821497  in combination  with SOC 
may be evaluated in patients with mCRPC (Part 2C).  
2.2.5.  [IP_ADDRESS]  Safety  Overview  
Preliminary data from the ongoing study, C2321001, indicate that PF -[ADDRESS_1121797]  frequently  reported  (≥15%)  all causality  TEAEs  across  all the tumor  types  and dose 
groups in single agent or in combination with SOC regimens were anemia  , nausea  
, thrombocytopenia  , diarrhea  , neutropenia  , fatigue  
, decreased appetite  , leukopenia  , asthenia and alopecia  CCI  
each),  dysgeusia  CCI , vomiting  CCI , and arthralgia  CCI . Note  that [ADDRESS_1121798]  frequently  reported  (≥10%)  PF-06821497  treatment  related  TEAEs  across  all the 
tumor types and dose groups were thrombocytopenia and nausea CCI  each), anemia  
CCI , neutropenia and diarrhea (CCI  each), fatigue and decreased appetite  CCI 
each),  dysgeusia  CCI , leukopenia  CCI , and alopecia and vomiting (CCI  each).  
Across the study the majority of the TEAEs reported were Grade 2 or lower. Of the 87 
patients,  23 (26.4%)  patients  reported  Grade  3 TEAEs,  24 (27.6%)  patients  reported  Grade  4 
TEAEs and 4 (4.6%) patients reported Grade 5 TEAEs. Of these TEAEs, 14 patients 
experienced Grade 3 TEAEs (16.1%) and 9 patients experienced Grade 4 TEAEs (10.3%) 
that were deemed related to study drug (PF -06821497).  
Across the study there were 52 SAEs (all -causality) reported in 33 participants. Of these 13 
SAEs reported in 7 patients were considered to be treatment related. SAEs reported were 
hepatic failure and sepsis (in one patient), thrombocytopenia and hemorrhagic disorder (in 
one patient),  acute  coronary  syndrome  (in one patient),  febrile  neutropenia  and pancytopenia 
(in one patient),  thrombocytopenia  and haemorrhage  (in one patient),  anemia  (in one patient) 
and electrocardiogram QT prolongation and presyncope (in one patient).  
Across  the study  there  were  12 deaths  reported  with eleven  (11) deaths  considered  unrelated 
to study treatment. One (1) event of hepatic failure was considered to be treatment -related.  
The event  of hepatic  failure  was reported  during  the trial and was considered  to be treatment - 
related. Hepatic failure with a fatal outcome occurred in a [COMPANY_003]  subject with 
CRPC enrolled in Cohort 2 (150 mg BID, single agent treatment of PF -06821497) who also 
developed significant increases in ALT, AST, bilirubin, and alkaline phosphatase associated 
with hepatic failure and sepsis. The etiology of hepatic failure is unclear. Liver 
transaminases, bilirubin, and alkaline phosphatase were initially normal at baseline, and 
began to significantly increase approximately [ADDRESS_1121799] [COMPANY_003]  developed cholestatic jaundice during the 
terminal course while receiving PF -06821497. Since the study  drug is temporally  associated, 
the possibility of a cholestatic reaction cannot be entirely excluded, but the presence of 
multiple other factors makes it impossible to attribute a definite cause in this case. This 
patient, along with the 86 other patients dosed (by [CONTACT_811040] 6 data cut off of 19 Nov 
2021) in the FIH study received PF -[ADDRESS_1121800] been reported for PF - 
06821497. As of the CTSUR/DSUR data cut off of [ADDRESS_1121801] 
been identified. Further details on the clinical safety information with PF -06821497 are 
provided in the current IB.  
2.2.6.  [IP_ADDRESS].  Summary of PF -[ADDRESS_1121802] dose (C1D1), and Day  15 morning dose (C1D15) are 
being evaluated in the ongoing study (C2321001). Preliminary NCA was conducted with 
draft concentration -time data (QC’d, non -QA’d) available as of 09 Nov 2021, using nominal 
times of sample collection and Phoenix WinNonlin version 8.2. Draft data of C1D1 and 
C1D15  from  patients  at 6 dose levels  (75 to 625 mg BID)  from  Part 1A and 1B, 4 dose levels 
(150 to 500 mg BID) from Part 2A SCLC, and 8 dose levels (150 to 250 mg BID) Part 2A 
CRPC of the study. PF -[ADDRESS_1121803]  decline with a  CCI  mean t1/2 ranging 
from  CCI  hours at single dose and CCI   after multiple dosing. Both single 
dose AUC inf and steady state AUC tau exhibit    . The interpatient 
variability  across  dose levels  (geometric  %CV)  for steady -state AUC tau ranges  from  CCI  
 
In Part 2A of C2321001,  PF-06821497  was given  in combination  with chemotherapy  (either 
carboplatin  or cisplatin)  to patients  with SCLC.  After  oral administration,  PF-[ADDRESS_1121804]  multi - 
phasic decline with a short mean t 1/[ADDRESS_1121805]  c 
decline with a CCI  mean t 1/2 ranging from CCI  hours at single dose and CCI   
after multiple dosing.  
Enzalutamide 160 mg QD is a strong inducer of CYP3A (as well as other enzymes and 
transporters) and CCI  PF-06821497 CCI  exposure  at steady  state after 
multiple dosing as compared to single dose. There is an approximate CCI  in 
PF-06821497 exposure (geometric mean steady  state AUC tau) when given as monotherapy  as 
compared  to when  given  in combination  with enzalutamide  at the same  respective  dose levels 
(150 mg BID to 500 mg BID).  
Further  details  on the clinical  PK of PF-06821497  are provided  in the current  IB. 
2.3. Benefit/Risk  Assessment  
PF-[ADDRESS_1121806] time that PF -06821497 will be administered to healthy adult 
participants. Prior to this study, PF -06821497 has been administered as monotherapy or in 
combination with other anti -cancer agents to advanced cancer patients at doses ranging from 
75 mg to 1250 mg BID continuously. Based on the results of the nonclinical toxicity studies 
(Section 2.2.3 ), the potential risk of PF -[ADDRESS_1121807] parameters for 
clinical  management,  including  study  drug discontinuation  as appropriate  to ensure  the safety 
of the study  participant.  Based  on the available  data from  Study  C2321001,  the clinical  safety 
profile favors further development of PF -06821497.  
More  detailed  information  about  the known  and expected  benefits  and risks  and reasonably 
expected AEs of PF -06821497 may be found in the IB, which is the SRSD for this study.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  29  
  
2.3.1.  Risk  Assessment  
 
Potential  Risk  of Clinical  Significance  Summary  of Data/Rationale  for Risk Mitigation  Strategy  
Study  Intervention(s)  PF-[ADDRESS_1121808]  been  crafted  to 
mitigate these identified potential risks (see 
Section 5 ). 
Potential  phototoxicity  effects  of PF-06821497  PF-06821497 absorbs in the UVA -UVB/visible 
range  from  290 to 700 nm with a calculated  MEC 
of >1000 L/(mol cm) and, as a result, could have 
photosafety risks.  The lifestyle  guidelines  for this protocol  include 
participant instructions to limit exposure to 
sunlight/high intensity ultraviolet light and use 
sunscreen products with high sun protection 
factor.  
Potential risks associated with PF -06821497 
include the following: GI toxicities (nausea, 
diarrhea), hematological (thrombocytopenia, 
nausea,  anemia,  neutropenia,),  hepatotoxicity,  and 
fatigue, decreased appetite, dysgeusia  The potential risks are based on emerging clinical 
data from the ongoing study C2321001 following 
continuous administration of PF -[ADDRESS_1121809] single  doses  of 
PF-06821497 and implement a washout period 
between doses across treatment periods to 
minimize  exposure  of PF-06821497  in the healthy 
participants.  
AEs and clinical  laboratory  results  will be 
monitored on an ongoing basis.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  30  
  
Potential  Risk  of Clinical  Significance  Summary  of Data/Rationale  for Risk Mitigation  Strategy  
Study  Procedures  
Blood  draws  for assessment  of PK, safety  labs, 
and retained samples.  A blood draw may cause participant discomfort 
including  faintness,  inflammation  of the vein,  pain, 
bruising, or bleeding at the site of puncture. There 
is also a slight chance of infection.  Blood  draws  will be performed  by [CONTACT_811041].  
Other  
The COVID -[ADDRESS_1121810] increased risk of SARS - 
CoV -2 infection  by [CONTACT_54215]  a study  procedure 
at a study facility.  Inclusion  of COVID -19 specific  assessments 
according to the SoA. 
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  31  
 3. OBJECTIVES  AND  ENDPOINTS  
Objectives  
Primary:   
 
 
 
Primary:   
 
Endpoints  
•  To estimate  the bioavailability  of a single  C  mg dose 
of PF -06821497  CC tablet formulation (Formulation 
2) relative to a single  C  mg dose of PF -06821497 
CCI tablet formulation (Formulation 1) under fasted 
conditions in adult healthy participants  
Secondary:  
•  To estimate the bioavailability of a single  C  mg 
dose of PF-06821497  CC tablet  (larger  API [INVESTIGATOR_811022])  formulation  (Formulation  3) relative  to a single 
C  mg dose of PF -06821497  CC tablet 
(Formulation 2) and  a single  C mg dose of the PF- 
06821497  CCI tablet formulation (Formulation 1) 
under fasted conditions in adult healthy participants  
 
• To estimate  the effect  of a high-fat, high-calorie  meal 
on the bioavailability  of a single  CCI mg dose of the 
PF-06821497  CC tablet  formulation  (Formulation  2) 
relative to fasted conditions in adult healthy 
participants  
 
• To estimate the effect of a low -fat, low -calorie meal 
on the bioavailability  of a single  CCI mg dose of the 
PF-06821497  CC tablet  formulation  (Formulation  2) 
relative  to fasted conditions in adult healthy 
participants  
• To evaluate the safety and tolerability of PF - 
06821497  when  administered  as a tablet  formulation 
to healthy participants  
CCI  • Plasma  AUC inf and Cmax for PF-06821497.  (AUC last will 
be used as the primary estimate if AUC inf cannot be 
reliably estimated).  
 
 
Secondary:  
• Plasma  AUC inf and Cmax for PF-06821497  for CC tablet 
(larger  API [INVESTIGATOR_811019])  (Formulation  3) relative  to CC 
(Formulation 2) and  CCI tablet (Formulation 1) 
formulations. (AUC last will be used as the primary 
estimate if AUC inf cannot be reliably estimated).  
 
 
 
• Plasma AUC inf and C max for PF -06821497 under fed 
(high -fat, high -calorie meal) conditions relative to 
fasting  conditions.  (AUC last will be used as the primary 
estimate if AUC inf cannot be reliably estimated).  
 
 
• Plasma AUC inf and C max for PF -06821497 under fed 
(low-fat, low-calorie  meal)  conditions  relative  to fasting 
conditions.  (AUC last will be used as the primary  estimate 
if AUC inf cannot be reliably estimated).  
 
• Assessment of TEAEs, clinical laboratory 
abnormalities,  vital signs,  physical  examinations,  and 
12-lead ECGs.  
 
 
 
 
4. STUDY  DESIGN  
4.1. Overall  Design  
This is a Phase  1, randomized,  open -label,  3-period,  crossover,  single -dose 2-part study  in 
healthyparticipants to investigate the effect of tablet formulation and food on the 
bioavailability of PF -06821497.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  32  
 In each part of the study, each enrolled participant will participate in 3 study periods to 
receive  3 different  treatments  according  to the sequence  determined  by [CONTACT_811034] 5- 
day washouts between PF -06821497 administration:  
Part  1 (rBA):  
• Treatment A – Single CCI mg dose CCI  tablet formulation 
(Formulation  1), under  fasting  conditions  (following  an overnight  fast of at least 10 
hours)  
• Treatment B – Single CCI mg dose CCI  tablet formulation 
(Formulation  2), under  fasting  conditions  (following  an overnight  fast of at least 10 
hours)  
• Treatment C – Single CCI mg dose CCI  tablet formulation (larger 
API [INVESTIGATOR_811019])  (Formulation  3), under  fasting  conditions  (following  an overnight 
fast of at least 10 hours)  
Part  2 (Food  Effect):  
• Treatment D – Single CCI  mg dose CCI  tablet formulation 
(Formulation  2), under  fasting  conditions  (following  an overnight  fast of at least 10 
hours)  
• Treatment E – Single CCI  mg dose CCI  tablet  formulation 
(Formulation 2), given with a low -fat/low -calorie meal  
• Treatment F – Single CCI  mg dose CCI  tablet  formulation 
(Formulation 2), given with a high -fat/high -calorie meal  
Approximately [ADDRESS_1121811] to the primary PK objective(s), additional participants can be enrolled at the 
discretion of the investigator upon consulation with the sponsor.  
In each part of the study, each enrolled participant will receive [ADDRESS_1121812] 10 hours and after the  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  33  
 C 
C 
C 
Treatment  A – CCI  formulation  (Formulation  1) 
Treatment B – CC  formulation (Formulation 2) 
Treatment C – CC  formulation (Formulation 3)  
C 
C 
C 
C 
fasted; 
fasted;  
; larger  API [INVESTIGATOR_811019])  fasted  ; 
 
 
 
 
C 
C 
C 
C 
E 
Washout: at 
least  C days 
between PF - 
06821497  doses  
Period  2 
 Washout:  at 
least  C days 
between  PF- 
06821497  
doses  
Period  1 
 Sequence  
D 
 1 (6 
Participants)  
F 
Period  [ADDRESS_1121813]  tablets  with 
approximately 240 mL of ambient temperature water. Tablets will be swallowed and not 
chewed. In each period, participants will undergo blood sampling for determination of PF - 
06821497  PK at timepoints  shown  in SoA. Participants  who withdraw  may be replaced  at the 
joint discretion of the investigator and the sponsor.  
 
Table 1.  Treatment  Schedule 
Part 1 (rBA):  
 
Sequence  Period  1 Washout:  at 
least  C days Period  2 Washout:  at 
least  C days Period  3 
1 (6 
Participants)  A between  
PF-06821497  
doses  B between  
PF-06821497  
doses  C 
2 (6 B  A  C 
Participants)       
 
 
 
 
Part  2 (Food  effect):  
 
Treatment  D – CC  formulation  (Formulation  2) fasted;  
Treatment  E – CC 
Treatment  F – CC formulation  (Formulation  2) fed: Low-fat meal;  
formulation  (Formulation  2) fed: High -fat meal 
 
In each part, participants will be on the study up to [ADDRESS_1121814] dose in each period following review of the discharge safety  
assessme nCtIs, provided  that the participants  are able to return  to the PCRU  on Day -1 for each 
of the remaining study periods. If a participant has any clinically significant study -related 
abnormalities at the conclusion of a scheduled inpatient portion of the study, the [COMPANY_007] 
medical  monitor  (or designated  representative)  should  be notified  and the participant  may be 
PF-[ADDRESS_1121815] to 
dosing with or without food, and to enable the establishment of the API [INVESTIGATOR_811017].  
Relative Bioavailability Assessment : In the ongoing clinical Phase 1 study (C2321001) for 
evaluating the safety and efficacy of PF -06821497, an  CCI  tablet formulation of PF - 
06821497 has been utilized. The current  CCI  tablet formulation (Formulation 1) has a  CCI 
drug loading with respect to the required pi[INVESTIGATOR_811023]. A new formulation of PF -06821497 manufactured using a  CCI  
process (Formulation 2) is planned to be used in the pi[INVESTIGATOR_9205] 2/3 trials. Therefore, the 
primary  objective  of the rBA study  is to compare  the relative  bioavailability  of the CCI  tablet 
formulation (Formulation 2) to that of  CCI  tablet formulation (Formulation 1) and confirm 
that they are comparable.  
The relative  bioavailability  of the CCI tablet  formulation  containing  an API [INVESTIGATOR_811024]  (Formulation 3)  CCI  relative to the WG tablet formulation  
(Formulation  2) and CCI tablet  formulation  (Formulation  1), containing  API [CONTACT_4490] a standard  
particle size CCI  will be evaluated  as a secondary  objective  of this study.  This 
comparison will enable the establishment of the API [INVESTIGATOR_811025].  
Food  effect  assessment:  Based  on the solubility  and permeability  data collected  in the pre- 
clinical phase, PF -[ADDRESS_1121816], due to CCI  
in fed state. Therefore, PK of the  tablet  formulation  (Formulation  2) following 
administration of a standard low -fat/low -calorie or high -fat/high -calorie meal will be 
evaluated as secondary objectives of this study to investigate the effect of food on the 
bioavailability of PF -06821497. The data from food effect assessment will inform dose 
administration instructions for PF -[ADDRESS_1121817] varying degree of fat content (eg, Breakfast 
versus dinner).  
PF-[ADDRESS_1121818] of food on PF -06821497 exposures 
based on its properties (BCS  CCI   compound,  CCI   is expected to be less than  CCI   
2. Therefore, there is a potential for this study  to generate     exposures  that may  be 
CCI   than what was observed in the FIP study. However, the single dose administration at 
mg is not expected  to have  significant  safety  concerns  even  if there  is a CCI  
in exposure, as PF -06821497 at CCI  mg/day CCI  has been tolerated following 
repeated administration with enzalutamide. Further, safety data from at least 3 participants 
from Part 2 Period 2 (where subjects will receive low -fat meal) will be reviewed before 
proceeding to Period 3 (high -fat meal condition) to provide an additional safeguard. In 
addition to the usual participant selection and safety monitoring measures implemented in 
such healthy volunteer studies, this study restricts the population to participants without a 
history of liver disease and with normal baseline liver tests, in accordance with FDA 
guidance provided during the course of the FIH study, in response to one patient developi[INVESTIGATOR_811026]-06821497. In addition, post treatment ECG monitoring has been added as additional 
measure,  as one case of G3 QTcF  prolongation,  potentially  related  to PF-[ADDRESS_1121819] 3 participants 
administered a low -fat meal in Period 2, will be reviewed by [CONTACT_811042].  Period  3 will initiate  as planned  if 
the doses administered in Period 2 were well -tolerated.  
4.2.2.  Choice  of Contraception/Barrier  Requirements  
Studies to evaluate the developmental toxicity of PF -[ADDRESS_1121820] not been conducted. 
Therefore,  the use of a highly  effective  method  of contraception  is required  (see Appendix  4). 
4.2.3.  Collection  of Retained  Research  Samples  
Retained  Research  Samples  will be collected  and stored  for further  analyses  which  may,  for 
example, provide greater understanding of the study intervention.  CCI 
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  36  
 CCI CCI CCI 4.3. Justification for Dose  
Part  1: A single  CCI mg dose of PF-06821497  is planned  for each period  in Part 1 (rBA)  of 
this study. A tablet strength of  CCI mg is being planned for the pi[INVESTIGATOR_811027] 1 of this study  is conducted at  CCI mg dose which is the single unit 
CCI  dose strength for the tablets being evaluated.  
Part 2:  A single  CCI  mg dose of PF -06821497 is planned for each period in Part 2 (food 
effect) of this study. Based on preliminary data from the ongoing Phase 1 study (C2321001) 
in advanced cancer patients, PF -[ADDRESS_1121821] of food on PF -06821497 exposures based on its properties (BCS CCI  
compound,  CCI  is expected to be    .[ADDRESS_1121822] 
significant safety concerns even if there is a CCI  in exposure, as  PF-06821497 at 
CCI  mg/day CCI   has been tolerated following repeated administration with 
enzalutamide. Preliminary analyses of data from C2321001 indicate that there is  
. In addition, based on 
preliminary PK data from C2321001 at  CCI  mg BID dose, the day 1 geometric mean and 
range of observed unbound C max of PF -06821497 is CCI  ng/mL, and CCI  ng/mL, 
respectively. If there is a CCI  in peak  exposures  by [CONTACT_8208],  it would  likely  result  in 
an unbound  Cmax of approximately  CCI ng/mL, which would  still be  CCI  the 
highest observed C max at CCI  mg dose in study C2321001. Considering the healthier 
population in this study  and PCRU confinement where more intense safety monitoring will 
be conducted, potential risks to study participants can be managed adequately and be 
mitigated with preventive measures in place that include routine monitoring of adverse 
events  and changes  in clinical  laboratory  test parameters  for clinical  management,  including 
study drug discontinuation as appropriate to ensure the safety of the study participants.  
Further,  safety  data from  at least 3 participants  from  Part 2 Period  2 (where  subjects  will 
receive low -fat meal) will be reviewed before proceeding to Period 3 (high -fat meal 
condition), where maximum food effect is expected, to provide an additional safeguard.  
PF-[ADDRESS_1121823] participants for whom participation in the study  is considered 
appropriate. All relevant medical and nonmedical conditions should be taken into 
consideration when deciding whether a particular participant is suitable for this protocol.  
Prospective  approval  of protocol  deviations  to recruitment  and enrollment  criteria,  also 
known as protocol waivers or exemptions, is not permitted.  
5.1. Inclusion  Criteria  
Participants  are eligible  to be included  in the study  only if all of the following  criteria  apply:  
Age and Sex: 
1. Participants  ≥18 years  of age, inclusive,  at screening.  
Refer  to Appendix  4 for reproductive  criteria  for male  (Section  10.4.1 ) and female 
(Section 10.4.2 ) participants.  
2. Male and female participants who are overtly healthy as determined by [CONTACT_811033],  physical  examination,  laboratory  tests,  vital 
signs and 12 -lead ECGs.  
Other Inclusion  Criteria:  
3. BMI  of ≥17.5  kg/m2; and a total  body  weight >50  kg (110 lb). 
4. Evidence  of a personally  signed  and dated  ICD indicating  that the participant  has 
been informed of all pertinent aspects of the study.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  38  
 5. Participants  who are willing  and able to comply  with all scheduled  visits,  treatment 
plan, laboratory tests, lifestyle considerations, and other study procedures.  
5.2. Exclusion  Criteria  
Participants  are excluded  from the  study  if any of the  following  criteria apply:  
Medical Conditions:  
1. Evidence or history of clinically significant hematological, renal, endocrine, 
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or 
allergic disease (including drug allergies, but excluding untreated, asymptomatic, 
seasonal  allergies  at the time of dosing)  or prior  allergic  reaction  to any component  of 
PF-06821497.  
• Any condition possibly affecting drug absorption (eg, gastrectomy, 
cholecystectomy,  prior  bariatric  surgery,  ileal resection,  inflammatory 
gastrointestinal  disease,  chronic  diarrhea,  known  diverticular  disease).  
• History  of HIV infection,  hepatitis  B, or hepatitis  C; positive  testing  for HIV, 
HBsAg, HBcAB or HCVAb. Hepatitis B vaccination is allowed.  
• Chronic liver diseases including alcoholic liver disease, viral hepatitis, 
primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune 
hepatitis,  Wilson’s  disease,  hemochromatosis,  alpha -1 antitrypsin  deficiency, 
human immunodeficiency virus, or other chronic liver disease.  
2. Other medical or psychiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory abnormality or other conditions or 
situations related to COVID -19 pandemic that may increase the risk of study 
participation  or, in the investigator’s  judgment,  make  the participant  inappropriate  for 
the study.  
Prior/Concomitant Therapy:  
3. Use of prescription  or nonprescription  drugs  and dietary  and herbal  supplements 
within  7 days or 5 half-lives  (whichever  is longer)  prior  to the first dose of study 
intervention.  (Refer  to Section  6.9 Prior  and Concomitant  Therapy  for additional 
details).  
• Current use or anticipated need for food or drugs that are known strong 
inducers or inhibitors of CYP3A4/5, including their administration within 10 
days or 5 half-lives  of the strong  inducer  or inhibitor  of CYP3A4/5,  whichever 
is longer prior to first dose of investigational product. Refer to Section 6.9 . 
• Time  dependent  inhibitors  of CYP3A4/[ADDRESS_1121824]  21 days prior  to the 
treatment  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  39  
 Prior/Concurrent Clinical Study Experience:  
4. Previous  administration  with an investigational  product  (drug  or vaccine) within  
30 days (or as determined  by [CONTACT_219873])  or [ADDRESS_1121825] 
dose of study intervention used in this study (whichever is longer).  
Diagnostic Assessments:  
5. A positive  urine  drug test. 
6. Screening  supi[INVESTIGATOR_145972] ≥140  mm Hg (systolic)  or ≥90 mm Hg (diastolic),  following  at 
least [ADDRESS_1121826]. If BP is ≥140 mm Hg (systolic) or ≥90 mm Hg 
(diastolic), the BP should be repeated 2 more times and the average of the 3 BP 
values should be used to determine the participant’s eligibility.  
7. Standard [ADDRESS_1121827] participant safety or interpretation of study results (eg, QTcF  >[ADDRESS_1121828] - degree AV 
block, or serious bradyarrhythmias or tachyarrhythmias). If the uncorrected QT 
interval  is >450  ms, this interval  should  be rate-corrected  using  the Fridericia  method 
only and the resulting QTcF should be used for decision making and reporting. If 
QTcF exceeds 450 ms, or QRS exceeds 120 ms, the ECG should be repeated twice 
and the average of the 3 QTcF or QRS values used to determine the participant’s 
eligibility. Computer -interpreted ECGs should be overread by a physician 
experienced in reading ECGs before excluding a participant.  
8. Participants  with ANY  of the following  abnormalities  in clinical  laboratory  tests at 
screening, as assessed by [CONTACT_22797] a single 
repeat test, if deemed necessary:  
• AST  or ALT  level  > ULN;  
• Total  bilirubin level >1 × ULN;  
• PT, INR  and aPTT  outside  of normal  limits  at baseline  
• eGFR  <60 mL/min/1.73  m2 based  on the CKD -EPI [INVESTIGATOR_10908];  
• Absolute neutrophil count <0.[ADDRESS_1121829].  
Other  Exclusion  Criteria:  
9. History of alcohol abuse or binge drinking and/or any other illicit drug use or 
dependence within 6 months of Screening. Binge drinking is defined as a pattern of 
5 (male)  and 4 (female)  or more  alcoholic  drinks  in about  2 hours.  As a general  rule, 
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  40  
 alcohol  intake  should  not exceed  14 units  per week  (1 unit = 8 ounces  (240 mL) beer, 
1 ounce (30 mL) of 40% spi[INVESTIGATOR_17040], or 3 ounces (90 mL) of wine).  
10. Use of tobacco or nicotine containing products within [ADDRESS_1121830] (ie, active  smokers  and those  who currently  use nicotine 
containing products are excluded from participation in this study).  
11. Pregnant female participants; breastfeeding female participants; fertile male 
participants and female participants of childbearing potential who are unwilling or 
unable  to use [ADDRESS_1121831].  
12. Blood  donation  (excluding  plasma  donations)  of approximately  1 pi[INVESTIGATOR_11731] (500 mL) or 
more within [ADDRESS_1121832] of the study and their family 
members.  
5.3. Lifestyle Considerations  
The following  guidelines  are provided:  
5.3.1.  Contraception  
The investigator or their designee, in consultation with the participant, will confirm that the 
participant is utilizing an appropriate method of contraception for the individual participant 
and their partner(s) from the permitted list of contraception methods (see Appendix 4 , 
Section  10.4.4 ) and will confirm  that the participant  has been  instructed  in its consistent  and 
correct use. At time points indicated in SoA, the investigator or designee will inform the 
participant of the need to use highly effective contraception consistently and correctly and 
document the conversation and the participant’s affirmation in the participant’s chart.  
Participants need to affirm their consistent and correct use of [ADDRESS_1121833] the participant to call immediately  if the 
selected contraception method is discontinued and document the requirement to use an 
alternate protocol -specified method, including if the participant will no longer use abstinence 
as the selected  contraception  method,  or if pregnancy  is known  or suspected  in the participant 
or partner.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  41  
 5.3.2.  Meals  and Dietary  Restrictions  
• Participants must abstain from all food and drink (except water) at least 4 hours prior 
to any safety  laboratory  evaluations  and 10 hours  prior  to the collection  of the predose 
PK sample on Day 1 of each Period.  
• Water is permitted until 1 hour prior to study  intervention administration. Water may 
be consumed  without  restriction  beginning  1 hour after dosing.  Noncaffeinated  drinks 
(except grapefruit or grapefruit -related citrus fruit juices —see below) may be 
consumed with meals and the evening snack . 
• There will be no predose water restriction for the fed treatment periods in Part 2 of 
the study (Treatment E and Treatment F) on Day 1. For Treatment E, following an 
overnight fast of at least 10 hours, participants will start the recommended low -fat 
(approximately  25% of total caloric  content  of the meal),  low-calorie  (approximately 
400 to 500 calories) breakfast [ADDRESS_1121834] will be consumed within an approximate 20 minute period with  
PF-06821497 administered approximately 10 minutes after completion of the meal. 
Participants  are strongly  encouraged  to consume  the low-fat/low -calorie  breakfast  in 
its entirety.  
• For Treatment F, following an overnight fast of at least 10 hours, participants will 
start the recommended high -fat (approximately 50% of total caloric content of the 
meal),  high-calorie  (approximately  800 to 1000  calories)  breakfast  [ADDRESS_1121835] will be consumed within an approximate 
20 minute period with PF -06821497 administered approximately 10 minutes after 
completion of the meal. Participants are strongly encouraged to consume the high - 
fat/high -calorie breakfast in its entirety.  
• Lunch  will be  provided approximately  4 hours  after PF -06821497 dosing.  
• Dinner  will be provided approximately  9 to 10 hours  after PF-06821497 dosing.  
• An evening snack may  be permitted.  
• Participants  will refrain  from  consuming  red wine  from  [ADDRESS_1121836] dose 
of study intervention until collection of the final PK blood sample.  
• While participants are confined, their total daily nutritional composition should be 
approximately 55% carbohydrate, 30% fat, and 15% protein with the exception for 
dosing days where a high fat/high calorie or low fat/low calorie meal will be given 
prior  to study  intervention.  The daily  caloric  intake  per participant  should  not exceed 
approximately 3200 kcal.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  42  
 5.3.3.  Caffeine,  Alcohol,  and Tobacco  
• Participants  will abstain  from  caffeine -containing  products  for 24 hours  prior  to the 
start of dosing until collection of the final PK sample of each study period.  
• Participants  will abstain  from  alcohol  for [ADDRESS_1121837] at the discretion of the investigator.  
5.3.4.  Activity  
• Participants will abstain from strenuous exercise (eg, heavy lifting, weight training, 
calisthenics,  aerobics)  for at least 48 hours  prior  to each blood  collection  for clinical 
laboratory tests. Walking at a normal pace will be permitted;  
• In order to standardize the conditions on PK sampling days, participants will be 
required to refrain from lying down (except when required for BP, pulse rate, and 
ECG  measurements),  eating,  and drinking  beverages  other  than water  during  the first 
4 hours after dosing.  
• Participants  will be advised  to report  any reaction  to sun exposed  skin.  In addition, 
special precautions will be taken to limit any potential photo irritation effect, by 
[CONTACT_811043],  tanning  booths  and sunlamps.  Participants  should  be 
encouraged to apply sunscreen/sunblock daily.  
• Participants  will be confined  to the procedure  room  for the first C hours  after dosing 
on Day  1 of Period 2 and 3 in Part 2 of the study, except to use the bathroom. After 
this, participants may be ambulatory but should not engage in strenuous activities.  
5.4. Screen  Failures  
Screen  failures  are defined  as participants  who consent  to participate  in the clinical  study  but 
are not subsequently enrolled in the study. Screen failure data are collected and remain as 
source and are not reported on the CRF.  
Individuals  who do not meet  the criteria  for participation  in this study  (screen  failure)  may be 
rescreened at the joint discretion of the investigator and medical monitor.  
6. STUDY  INTERVENTION(S)  AND  CONCOMITANT  THERAPY  
Study interventions are all prespecified investigational and noninvestigational medicinal 
products,  medical  devices,  and other  interventions  (eg, surgical  and behavioral)  intended  to 
be administered to the study participants during the study conduct.  
For the purposes  of this protocol,  study  intervention  refers  to PF-06821497  tablets.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  43  
 
CCI 
CCI 
CCI 
CCI 
CCI 
CCI 
CCI 
CCI 
CCI 
CCI 6.1. Study  Intervention(s)  Administered  
For this study, the study interventions are the tablet formulations of PF -06821497 
administered as single dose (CCI mg in Part 1,  CCI  mg in Part 2) under fasted or fed 
conditions; Treatment A [CCI  mg of   tablet formulation (Formulation 1), under 
fasting conditions], Treatment B [  mg of  CCI  tablet formulation (Formulation 2), 
under fasting conditions], Treatment C [    of CCI  tablet  formulation  (larger  API 
[INVESTIGATOR_811018]) (Formulation 3), under fasting conditions], Treatment D [  mg of CCI 
tablet  formulation  (Formulation  2), under  fasting  conditions],  Treatment  E  mg of 
tablet  formulation  (Formulation  2), given  with a low-fat/low -calorie  meal],  Treatment  F 
[ mg of  tablet formulation (Formulation 2), given with a high -fat/high -calorie 
meal]. The PF -06821497 tablet formulations will be supplied by [CONTACT_4618].  
PF-06821497  CCI mg strength tablets for the 3 tablet formulations will be supplied to the 
PCRU  in bulk along  with individual  dosing  containers  for unit dosing.  A brief  description  of 
the PF -06821497 tablet formulations supplied in this study is provided in Table 2.  
 
Table  2. Summary  of PF-06821497  Formulations  
 
Description  Material  ID (DMID)/  Lot 
Number  Included in 
Treatment(s)  Route of 
Administration  
PF-06821497  CCI  DP-001550/22 -DP-[ZIP_CODE]  Treatment  A Oral 
tablets  (Formulation  1) 
PF-06821497  CCI  DP-005872/23 -DP-[ZIP_CODE]  Treatment  B, D, E and 
F Oral 
tablets  (Formulation  2) 
PF-06821497  CCI  DP-005872/23 -DP-[ZIP_CODE]  Treatment  C Oral 
tablets  (larger  API [INVESTIGATOR_811028])  (Formulation  3) 
 
6.1.1.  Administration 
All Treatment  Periods:  
Investigator site personnel will administer study intervention during each period with 
ambient temperature water to a total volume of approximately 240 mL. Participants will 
swallow  the study  intervention  whole,  and will not manipulate  or chew  the study  intervention 
prior to swallowing.  
In order to standardize the conditions on PK sampling days, all participants will be required 
to refrain from lying down (except when required for BP, pulse rate, and ECG 
measurements),  eating,  and drinking  beverages  other  than water  during  the first 4 hours  after 
dosing.  
Treatment  A  tablets (Formulation 1) , fasting conditions]:  
Following  an overnight  fast of at least 10 hours  and after the collection  of the predose  PK 
sample on Day  1, participants will take a single  mg dose CCI mg tablets)  of the 
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  44  
 CCI  tablet  formulation  (Formulation  1) of PF-06821497  at approximately  0800  hours  (plus 
or minus 2 hours).  
Treatment  B [CCI   tablets (Formulation 2), fasting conditions]:  
Following an overnight fast of at least 10 hours and after the collection of the predose PK 
sample on Day 1, participants will take a single  CCI mg dose (CCI  mg tablets)  of the CCI  
tablet formulation (Formulation 2) of PF -06821497 at approximately 0800 hours (plus or 
minus 2 hours).  
Treatment C CCI   tablets  (larger  API [INVESTIGATOR_811019])  (Formulation  3), fasting  
conditions]:  
Following an overnight fast of at least 10 hours and after the collection of the predose PK 
sample on Day 1, participants will take a single  CCI mg dose (CCI  mg tablets)  of the CCI  
tablet formulation (larger API [INVESTIGATOR_811018]) (Formulation 3) of PF -06821497 at 
approximately 0800 hours (plus or minus 2 hours).  
Treatment  D [CCI   tablets (Formulation 2) , fasting conditions]:  
Following an overnight fast of at least 10 hours and after the collection of the predose PK 
sample on Day 1, participants will take a single CCI  mg dose  CCI  mg tablets) of the 
CCI  tablet  formulation  (Formulation  2) of PF-06821497  at approximately  0800  hours  (plus 
or minus 2 hours).  
Treatment  E [CCI   tablets (Formulation 2), fed conditions: low -fat meal]:  
Following  an overnight  fast of at least 10 hours,  participants  will start the recommended  low- 
fat (approximately  25% of total caloric content of the meal), low -calorie (approximately  400 
to 500 calories) breakfast 30 minutes prior to administration of the  CCI  tablet formulation 
(Formulation 2) of PF -06821497. Breakfast will be consumed within an approximate 20 
minute  period  with PF-06821497  administered  approximately  10 minutes  after completion  of 
the meal. Participants are strongly encouraged to consume the low -fat/low -calorie breakfast 
in its entirety. Percentage of the meal consumed will be documented in the CRF. PF - 
06821497 should be administered at approximately 0800 hours (plus or minus 2 hours).  
Treatment  F [CCI   tablets (Formulation 2), fed conditions: high -fat meal]:  
Following an overnight fast of at least 10 hours, participants will start the recommended 
high-fat (approximately 50% of total caloric content of the meal), high -calorie 
(approximately  800 to 1000  calories)  breakfast  30 minutes  prior  to administration  of the CCI  
tablet formulation (Formulation 2) of PF -06821497. Breakfast will be consumed within an 
approximate 20 minute period with PF -06821497 administered approximately 10 minutes 
after completion of the meal. Participants are strongly encouraged to consume the high - 
fat/high -calorie  breakfast  in its entirety.  Percentage  of the meal  consumed  will be 
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  45  
 documented  in the CRF.  PF-06821497  should  be administered  at approximately  0800  hours 
(plus or minus 2 hours).  
6.2. Preparation,  Handling,  Storage,  and Accountability  
1. The investigator or designee must confirm that appropriate conditions (eg, 
temperature)  have  been  maintained  during  transit  for all study  interventions  received 
and any discrepancies  are reported  and resolved  before  use of the study  intervention.  
2. Only  participants  enrolled  in the study  may receive  study  intervention  and only 
authorized site staff may  supply, prepare, and/or administer study  intervention.  
3. All study interventions must be stored in a secure, environmentally controlled, and 
monitored (manual or automated recording) area in accordance with the labeled 
storage conditions with access limited to the investigator and authorized site staff. At 
a minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonworking days must 
indicate  the minimum  and maximum  temperatures  since  previously  documented  upon 
return to business.  
4. Any excursions from the study intervention label storage conditions should be 
reported to [COMPANY_007] upon discovery  along with actions taken. The site should actively 
pursue  options  for returning  the study  intervention  to the labeled  storage  conditions, 
as soon as possible. Once an excursion is identified, the study intervention must be 
quarantined and not used until [COMPANY_007] provides permission to use the study 
intervention. Specific details regarding the excursion definition and information to 
report for each excursion will be provided to the site in the PCRU local/site 
procedures.  
5. Any storage  conditions  stated  in the SRSD  will be superseded  by [CONTACT_78254].  
6. Study  interventions  should  be stored  in their original  containers.  
7. The investigator,  institution,  head  of the medical  institution  (where  applicable),  or 
authorized site staff is responsible for study intervention accountability, 
reconciliation, and record maintenance (ie, receipt, reconciliation, and final 
disposition records), such as the IPAL or sponsor -approved equivalent. All study 
interventions will be accounted for using a study intervention accountability 
form/record.  
8. Further guidance and information for the final disposition of unused study 
interventions  are provided  in the PCRU’s  local/site  procedures.  All destruction  must 
be adequately documented. If destruction is authorized to take place at the 
investigator site, the investigator must ensure that the materials are destroyed in 
compliance with applicable environmental regulations, institutional policy, and any 
special instructions provided by [CONTACT_4618].  
PF-[ADDRESS_1121838]  complaint,  notify  the sponsor  within  1 business  day of 
discovery.  
6.2.1.  Preparation  and Dispensing  
Within  this protocol,  preparation  refers  to the investigator  site activities  performed  to make 
the study  intervention ready  for administration or dispensing to the participant by  [CONTACT_216479]. Dispensing is defined as the provision of study  intervention, concomitant treatments, 
and accompanying information by [CONTACT_22806](s) to a healthcare provider, 
participant, in accordance with this protocol. Local health authority regulations or 
investigator site guidelines may use alternative terms for these activities.  
PF-06821497  tablets  will be prepared  at the CRU  in the individual  dosing  containers by 
2 operators, 1 of whom is an appropriately qualified and experienced member of the study 
staff (eg, physician, nurse, physician’s assistant, nurse practitioner, pharmacy 
assistant/technician,  or pharmacist).  The tablets  will be provided  in unit dose containers  and 
labeled in accordance with [COMPANY_007] regulations and the clinical site’s labeling requirements.  
6.3. Assignment  to Study  Intervention  
The investigator’s  knowledge  of the treatment  should  not influence  the decision  to enroll  a 
particular participant or affect the order in which participants are enrolled.  
The investigator will assign participant numbers to the participants as they are screened for 
the study.  [COMPANY_007]  will provide  a randomization  schedule  to the investigator  and, in accordance 
with the randomization numbers, the participant will receive the study treatment regimen 
assigned to the corresponding randomization number.  
6.4. Blinding  
This is an open -label  study.  
6.5. Study  Intervention  Compliance  
When  the individual  dose for a participant  is prepared  from  a bulk supply,  the preparation  of 
the dose will be confirmed by a second qualified member of the study site staff.  
Participants will be dosed at the site and receive study intervention directly from the 
investigator or designee, under medical supervision. The date and time of each dose 
administered  in the clinic  will be recorded  in the source  documents  and recorded  in the CRF. 
The dose of study intervention and study participant identification will be confirmed at the 
time of dosing by a member of the study site staff other than the person administering the 
study  intervention.  Study  site personnel  will examine  each participant’s  mouth  to ensure  that 
the study intervention was ingested.  
6.6. Dose Modification  
No dose modification  is anticipated.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  47  
 6.7. Continued  Access  to Study Intervention  After  the End of the Study  
No study  intervention will be provided to participants at the end of their study  participation.  
6.8. Treatment  of Overdose  
For this study, any  dose of PF-06821497 greater  than CCI mg in Part 1 and CCI  mg in Part 2 
within a 24 -hour time period ±6 hours will be considered an overdose.  
There  is no specific treatment  for a PF-06821497  overdose.  
In the event  of an overdose,  the investigator/treating  physician  should:  
1. Contact  [CONTACT_219876] 24 hours.  
2. Closely  monitor  the participant  for any AEs/SAEs  and laboratory  abnormalities  as 
medically appropriate and at least until the next scheduled follow -up. 
3. Document  the quantity  of the excess  dose as well as the duration  of the overdose  in 
the CRF.  
4. Overdose is reportable to [COMPANY_007] Safety  only when associated with an SAE.  
5. Obtain  a blood  sample  for PK analysis  within  C days from  the date of the last dose of 
study  intervention if requested by [CONTACT_138830] (determined on a  
case-by-case basis).  
6.9. Prior  and Concomitant  Therapy  
Use of prescription or nonprescription drugs and dietary and herbal supplements are 
prohibited within 7 days or 5 half -lives (whichever is longer) prior to the first dose of study 
intervention. Limited use of nonprescription medications that are not believed to affect 
participant  safety  or the overall  results  of the study  may be permitted  on a case-by-case basis 
following approval by [CONTACT_456] . Acetaminophen/paracetamol may be used at doses of  
≤1 g/day.  
As PF -06821497 is primarily metabolized by [CONTACT_097]3A4/5, as determined in in vitro studies, 
concomitant use of any medications or substances that are strong inducers or inhibitors of 
CYP3A4/[ADDRESS_1121839] dose of PF -06821497.  
Strong CYP3A4/5 inhibitors may include grapefruit juice or grapefruit/grapefruit related 
citrus fruits (eg, Seville oranges, pomelos), ketoconazole, miconazole, itraconazole, 
voriconazole,  posaconazole,  clarithromycin,  telithromycin,  indinavir,  saquinavir,  ritonavir, 
nelfinavir,  amprenavir,  fosamprenavir,  nefazodone,  lopi[INVESTIGATOR_054],  troleandomycin,  mibefradil, 
and conivaptan.  
Strong  CYP3A4/[ADDRESS_1121840]. John’s Wort.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  48  
 Time dependent inhibitors of CYP3A4/[ADDRESS_1121841] 21 days prior to the 
treatment.  Time  dependent  inhibitors  of CYP3A4/5  may include  azamulin,  troleandomycin, 
verapamil, boceprevir, nelfinavir, and telaprevir.  
It is preferred that moderate CYP3A4/5 inhibitors and/or inducers be replaced prior to the 
first dose of study treatment and during study conduct.  Moderate CYP3A4/5 inhibitors may 
include  erythromycin,  ciprofloxacin,  verapamil,  diltiazem,  atazanavir,  fluconazole,  darunavir, 
delavirdine, amprenavir, fosamprenavir, aprepi[INVESTIGATOR_053], imatinib, tofisopam, and cimetidine.  
Moderate  CYP3A4/5  inducers  may include  bosentan,  efavirenz,  etravirine,  modafinil,  and 
nafcillin.  If the replacement is not possible, then caution should be exercised with 
coadministration of PF -06821497 with moderate CYP3A4/5 inhibitors and/or inducers.  
Additionally,  concomitant  use of PF-06821497  and a substrate  of the CCI  renal  
transporter may  increase the exposure of the  CCI substrate.  Therefore, caution is 
warranted  if coadministration  of PF-06821497 with  CCI  substrates.  
Hormonal  contraceptives  that meet  the requirements  of this study  are allowed  to be used in 
participants who are WOCBP (see Appendix 4 ). 
All concomitant  treatments  taken  during  the study  must  be recorded  with indication,  daily 
dose, and start and stop dates of administration. All participants will be questioned about 
concomitant treatment at each clinic visit.  
Treatments taken within [ADDRESS_1121842] dose of study  intervention 
will be documented as concomitant treatments.  
6.9.1.  Rescue  Medicine  
There  is no rescue  therapy  to reverse  the AEs observed  with PF-06821497;  standard  medical 
supportive care must be provided to manage the AEs.  
7. DISCONTINUATION  OF STUDY  INTERVENTION  AND  PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  
7.1. Discontinuation  of Study  Intervention  
It may be necessary  for a participant  to permanently  discontinue  study  intervention.  Reasons 
for permanent discontinuation of study intervention include the following:  
• AE requiring  discontinuation  in investigator’s  view;  
• Positive  COVID -[ADDRESS_1121843]. 
If study  intervention  is permanently  discontinued,  the participant  will not remain  in the study 
for further evaluation. See the SoA for data to be collected at the time of discontinuation of 
the study intervention.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  49  
 7.1.1.  COVID -19 
If a participant  has COVID -19 during  the study,  this should  be reported  as an AE or SAE  (as 
appropriate) and appropriate medical intervention provided. Temporary discontinuation of 
the study  intervention may  be medically appropriate until the participant has recovered from 
COVID -19. 
It is recommended  that the investigator  discuss  temporary  or permanent  discontinuation  of 
study intervention with the study medical monitor.  
7.2. Participant  Discontinuation/Withdrawal  From  the Study  
A participant  may withdraw  from  the study  at any time at their own request.  Reasons  for 
discontinuation from the study include the following:  
• Refused  further  study  procedures;  
• Lost to follow -up; 
• Death;  
• Study  terminated by  [CONTACT_3211];  
• Investigator’s  decision.  
At the time of discontinuing  from  the study,  if possible,  an early  discontinuation  visit should 
be conducted. See the SoA for assessments to be collected at the time of study 
discontinuation and follow -up and for any further evaluations that need to be completed.  
The early  discontinuation  visit applies  only to participants  who are enrolled/randomized  and 
then are prematurely  withdrawn  from  the study.  Participants  should  be questioned  regarding 
their reason for withdrawal.  
The participant  will be permanently  discontinued  from  the study  intervention  and the study  at 
that time.  
If a participant withdraws from the study, they may request destruction of any remaining 
samples  taken  and not tested,  and the investigator  must  document  any such requests  in the 
site study records and notify the sponsor accordingly.  
If the participant  withdraws  from  the study  and also withdraws  consent  (see Section  7.2.1) 
for disclosure of future information, no further evaluations will be performed and no 
additional data will be collected. The sponsor may retain and continue to use any data 
collected before such withdrawal of consent.  
7.2.1.  Withdrawal of  Consent  
Participants  who request  to discontinue  receipt  of study  intervention  will remain  in the study 
and must continue to be followed for protocol -specified follow -up procedures. The only 
exception  to this is when  a participant  specifically  withdraws  consent  for any further  contact  
[INVESTIGATOR_16335]-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  50  
 with them or persons previously authorized by [CONTACT_104140]. 
Participants should notify the investigator in writing of the decision to withdraw consent 
from future follow -up, whenever possible. The withdrawal of consent should be explained in 
detail in the medical records by [CONTACT_093], as to whether the withdrawal is only from 
further  receipt  of study  intervention  or also from  study  procedures  and/or  posttreatment  study 
follow -up, and entered on the appropriate CRF page. In the event that vital status (whether 
the participant is alive or dead) is being measured, publicly available information should be 
used to determine vital status only as appropriately directed in accordance with local law.  
7.3. Lost  to Follow -up 
A participant  will be considered  lost to follow -up if the participant  repeatedly  fails to return 
for scheduled visits and is unable to be contact[CONTACT_9298].  
The following  actions  must  be taken  if a participant  fails to attend  a required  study  visit:  
• The site must attempt to contact [CONTACT_14315]. Counsel the participant on the importance of maintaining the 
assigned  visit schedule  and ascertain  whether  the participant  wishes  to and/or  should 
continue in the study;  
• Before a participant is deemed lost to follow -up, the investigator or designee must 
make  every  effort  to regain  contact  [CONTACT_6635]  (where  possible,  3 telephone 
calls and, if necessary, a certified letter to the participant’s last known mailing 
address  or local equivalent methods). These contact [CONTACT_219880]’s medical record;  
• Should  the participant  continue  to be unreachable,  the participant  will be considered 
to have withdrawn from the study.  
8. STUDY ASSESSMENTS AND  PROCEDURES  
8.1. Administrative  Procedures  
The investigator  (or an appropriate  delegate  at the investigator  site) must  obtain  a signed  and 
dated ICD before performing any study -specific procedures.  
Study  procedures  and their timing  are summarized  in the SoA. Protocol  waivers  or 
exemptions are not allowed.  
Adherence  to the study  design  requirements,  including  those  specified  in the SoA, is essential 
and required for study conduct.  
All screening evaluations must be completed and reviewed to confirm that potential 
participants  meet  all eligibility  criteria.  The investigator  will maintain  a screening  log to 
record  details  of all participants  screened  and to confirm  eligibility  or record  reasons  for 
screening failure, as applicable.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  51  
 Participants will be screened within 28 days prior to administration of the study  intervention 
to confirm that they meet the study population criteria for the study. If the time between 
screening and dosing exceeds 28 days as a result of unexpected delays (eg, delayed drug 
shipment),  then participants  do not require  rescreening  if the laboratory  results  obtained  prior 
to first dose administration meet eligibility criteria.  
A participant  who qualified  for this protocol  but did not enroll  from  an earlier  cohort/group 
may be used in a subsequent cohort/group without rescreening, provided laboratory  results 
obtained prior to the first dose administration meet eligibility criteria for this study. In 
addition, other clinical assessments or specimen collections, eg, retained research samples, 
may be used without repeat collection, as appropriate.  
Every effort should be made to ensure that protocol -required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may be 
circumstances outside the control of the investigator that make it unfeasible to perform the 
test. In these cases, the investigator must take all steps necessary to ensure the safety and 
well-being of the participant. When a protocol -required test cannot be performed, the 
investigator  will document  the reason  for the missed  test and any corrective  and preventive 
actions that they have taken to ensure that required processes are adhered to as soon as 
possible. The study team must be informed of these incidents in a timely manner.  
If an IV catheter  is utilized  for blood  sample  collections,  ECGs  and vital sign assessments 
(pulse rate and BP) should be collected prior to the insertion of the catheter.  
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment  instructions  and contact  [CONTACT_219881].  
The total blood sampling volume for individual participants in this study is approximately 
230 mL. The actual collection times of blood sampling may change. Additional blood 
samples may  be taken for safety assessments at times specified by [CONTACT_4618], provided the total 
volume  taken  during  the study  does not exceed  550 mL during  any period  of 56 consecutive 
days.  
To prepare  for study  participation,  participants  will be instructed  on the information  in the 
Lifestyle Considerations and Concomitant Therapy sections of the protocol.  
8.2. Efficacy  Assessments  
Not applicable.  
8.3. Safety  Assessments  
Planned  time points  for all safety  assessments  are provided  in the SoA. Unscheduled  safety 
measurements may  be obtained at any  time during the study  to assess any  perceived safety 
issues.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  52  
 8.3.1.  Physical Examinations  
A complete  physical  examination  will include,  at a minimum,  head,  ears, eyes,  nose,  mouth, 
skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and 
neurological systems.  
A brief  physical  examination  will include,  at a minimum,  assessments  of general  appearance, 
the respi[INVESTIGATOR_110251], and participant -reported symptoms.  
Physical  examinations  may be conducted  by a physician,  trained  physician’s  assistant,  or 
nurse practitioner as acceptable according to local regulation.  
Height  and weight  will also be measured  and recorded  as per the SoA. For measuring  weight, 
a scale with appropriate range and resolution is used and must be placed on a stable, flat 
surface. Participants must remove shoes, bulky layers of clothing, and jackets so that only 
light clothing remains. They must also remove the contents of their pockets and remain still 
during measurement of weight.  
Physical  examination  findings  collected  during  the study  will be considered  source  data and 
will not be required to be reported, unless otherwise noted. Any untoward physical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE ( Appendix 3 ) must be reported according to the processes in 
Sections 8.4.1  to 8.4.3 . 
8.3.2.  Vital Signs  
[IP_ADDRESS].  Blood  Pressure  and Pulse  Rate  
Supi[INVESTIGATOR_219848]’s  arm supported  at the level  of the heart,  and 
recorded to the nearest mm Hg after approximately [ADDRESS_1121844]. The same arm 
(preferably the dominant arm) will be used throughout the study. Participants should be 
instructed not to speak during measurements.  
The same  properly  sized  and calibrated  BP cuff will be used to measure  BP each time.  The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manually, pulse rate will be measured in the brachial/radial artery for at least  
[ADDRESS_1121845]  vital sign findings  that are identified  during  the active  collection  period  and 
meet the definition of an  AE or SAE ( Appendix 3 ) must be reported according to the 
processes in Sections 8.4.1  to 8.4.3 . 
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  53  
 [IP_ADDRESS].  Respi[INVESTIGATOR_811029]  [ADDRESS_1121846] and before BP measurement.  
[IP_ADDRESS].  Temperature  
Temperature  will be measured  orally.  No eating  or drinking  is allowed  for [ADDRESS_1121847] 12 -lead ECGs utilizing limb leads (with a 10 -second rhythm strip) should be 
collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically calculates the HR and measures PR interval, QT interval, QTcF, and QRS 
complex. Alternative lead placement methodology using torso leads (eg, Mason -Likar) 
should not be used given the potential risk of discrepancies with ECGs acquired using 
standard  limb lead placement.  All scheduled  ECGs  should  be performed  after the participant 
has rested quietly for at least 5 minutes in a supi[INVESTIGATOR_2547].  
To ensure  safety  of the participants,  a qualified  individual  at the investigator  site will make 
comparisons to baseline measurements (from within the current Treatment Period).  
Additional  ECG  monitoring  will occur  if a) a postdose  QTcF  interval  is increased  by ≥60 ms 
from the baseline and is >450 ms; or b) an absolute QT value is ≥[ADDRESS_1121848] hourly until QTc values from 2 successive ECGs fall below the threshold 
value that triggered the repeat measurement.  
If a) a postdose QTcF interval remains ≥60 ms from the baseline and is >450 ms; or b) an 
absolute  QT value  is ≥500  ms for any scheduled  ECG  for greater  than 4 hours  (or sooner,  at 
the discretion  of the investigator);  or c) QTcF  value  get progressively  longer,  the participant 
should undergo continuous ECG monitoring. A cardiologist should be consulted if QTcF 
values do not return to less than the criteria listed above after 8 hours of monitoring (or 
sooner, at the discretion of the investigator).  
In some cases, it may be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads be placed in the 
same  positions  each time in order  to achieve  precise  ECG  recordings.  If a machine  -read QTc 
value is prolonged, as defined above, repeat measurements may not be necessary if a 
qualified medical provider’s interpretation determines that the QTcF values are in the 
acceptable range.  
ECG  values  of potential  clinical  concern  are listed  in Appendix 8. 
PF-[ADDRESS_1121849] findings are those that are not associated with 
the underlying  disease,  unless  judged  by [CONTACT_219882]’s condition.  
All laboratory tests with values considered clinically significant and abnormal during 
participation in the study or within [ADDRESS_1121850] dose of study intervention should  
be repeated  until the values  return  to normal  or baseline  or are no longer  considered  clinically 
significant by [CONTACT_219883].  
If such values  do not return  to normal/baseline  within  a period  of time judged  reasonable  by 
[CONTACT_093], the etiology should be identified and the sponsor notified.  
See Appendix  [ADDRESS_1121851] 25 mIU/mL. Pregnancy tests 
will be performed  in WOCBP  at the times  listed  in the SoA. Following  a negative  pregnancy 
test result  at screening,  appropriate  contraception  must  be commenced  and a second  negative 
pregnancy test result will be required at the baseline visit prior to the participant’s receiving 
the PF -06821497. Pregnancy tests will also be done whenever 1 menstrual cycle is missed 
during the active treatment period (or when potential pregnancy is otherwise suspected) and 
at the end of the study. Pregnancy tests may also be repeated if requested by [CONTACT_1202]/ECs or if 
required by [CONTACT_427]. If a urine test cannot be confirmed as negative (eg, an  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  55  
 ambiguous  result),  a serum  pregnancy  test is required.  In such cases,  the participant  must  be 
excluded if the serum pregnancy result is positive.  
8.4. Adverse  Events,  Serious  Adverse  Events,  and Other  Safety  Reporting  
The definitions  of an AE and  an SAE  can be found  in Appendix 3. 
AEs may arise from symptoms or other complaints reported to the investigator by [CONTACT_2416] (or, when appropriate, by a caregiver, surrogate, or the participant’s legally 
authorized  representative),  or they may arise  from  clinical  findings  of the investigator  or 
other healthcare providers (clinical signs, test results, etc).  
The investigator  and any qualified  designees  are responsible  for detecting,  documenting,  and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
the study (see Section 7.1 ). 
During  the active  collection  period  as described  in Section  8.4.1,  each participant  will be 
questioned about the occurrence of AEs in a nonleading manner.  
In addition,  the investigator  may be requested  by [CONTACT_219887] -up 
information in an expedited fashion.  
8.4.1.  Time  Period  and Frequency  for Collecting  AE and SAE  Information  
The time period for actively eliciting and collecting AEs and SAEs (“active collection 
period”)  for each participant  begins  from  the time the participant  provides  informed  consent, 
which is obtained before undergoing any study -related procedure and/or receiving study 
intervention), through and including a minimum of [ADDRESS_1121852] SAE Report Form.  
[IP_ADDRESS].  Reporting  SAEs  to [COMPANY_007] Safety  
All SAEs occurring in a participant during the active collection period as described in 
Section  8.4.[ADDRESS_1121853] SAE  Report  Form  immediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3 . The investigator will submit any updated SAE data to the sponsor within  
24 hours  of its being  available.  
[IP_ADDRESS].  Recording  Nonserious  AEs and SAEs  on the CRF  
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which  begins  after obtaining  informed  consent  as described  in Section  8.4.[ADDRESS_1121854]  to the CRF 
requirements as described in Section 5.4 . 
8.4.2.  Method  of Detecting  AEs and SAEs  
The method  of recording,  evaluating,  and assessing  causality  of AEs and SAEs  and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 . 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading  verbal  questioning  of the participant  is the preferred  method  to inquire  about  AE 
occurrences.  
8.4.3.  Follow -Up of AEs and SAEs  
After the initial AE or SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain  adequate  information  until resolution,  stabilization,  the event  is otherwise  explained, 
or the participant is lost to follow -up (as defined in Section 7.3 ). 
PF-[ADDRESS_1121855]  the safety  of participants  and the safety  of a 
study intervention under clinical investigation are met.  
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies  about  the safety  of a study  intervention  under  clinical  investigation.  The 
sponsor will comply with country -specific regulatory requirements relating to safety 
reporting to the regulatory authority, IRBs/ECs, and investigators.  
Investigator  safety  reports  must  be prepared  for S[LOCATION_003]Rs  according  to local  regulatory 
requirements and sponsor policy and forwarded to investigators as necessary.  
An investigator who receives S[LOCATION_003]Rs or other specific safety information (eg, summary  or 
listing  of SAEs)  from  the sponsor  will review  and then file it along  with the SRSD(s)  for the 
study and will notify the IRB/EC, if appropriate according to local requirements.  
8.4.5.  Environmental  Exposure,  Exposure  During  Pregnancy  or Breastfeeding,  and 
Occupational Exposure  
Environmental exposure, occurs when a person not enrolled in the study as a participant 
receives unplanned direct contact [CONTACT_273478]. Such exposure 
may or may not lead to the occurrence of an AE or SAE. Persons at risk for environmental 
exposure  include  healthcare  providers,  family  members,  and others  who may be exposed.  An 
environmental exposure may include EDP, EDB, and occupational exposure.  
Any such exposures  to the study  intervention  under  study  are reportable  to [COMPANY_007]  Safety 
within 24 hours of investigator awareness.  
[IP_ADDRESS].  Exposure During Pregnancy  
An EDP  occurs  if: 
• A female  participant  is found  to be pregnant  while  receiving  or after discontinuing 
study intervention . 
• A male  participant  who is receiving  or has discontinued  study  intervention 
inseminates a female partner.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  58  
 • A female  nonparticipant  is found  to be pregnant  while  being  exposed  or having  been 
exposed to study intervention because of environmental exposure. Below are 
examples of environmental EDP:  
• A female  family  member  or healthcare  provider  reports  that she is pregnant  after 
having been exposed to the study intervention by [CONTACT_78262], inhalation, or skin 
contact.  
• A male  family  member  or healthcare  provider  who has been  exposed  to the study 
intervention by  [CONTACT_78262], inhalation, or skin contact [CONTACT_336270].  
The investigator must report EDP to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness,  irrespective  of whether  an SAE  has occurred.  The initial  information  submitted 
should include the anticipated date of delivery (see below for information related to 
termination of pregnancy).  
• If EDP  occurs  in a participant  or participant’s  partner,  the investigator  must  report 
this information to [COMPANY_007] Safety on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details of the 
pregnancy  will be collected after the start of study  intervention and until [ADDRESS_1121856] dose.  
• If EDP  occurs  in the setting  of environmental  exposure,  the investigator  must  report 
information  to [COMPANY_007]  Safety  using  the CT SAE  Report  Form  and EDP  Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study, the information is not recorded on a CRF; however, a copy of the 
completed CT SAE Report Form is maintained in the investigator site file.  
Follow -up is conducted to obtain general information on the pregnancy and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy termination) and notify [COMPANY_007] Safety of the outcome as a 
follow -up to the initial EDP Supplemental Form. In the case of a live birth, the structural 
integrity  of the neonate  can be assessed  at the time of birth.  In the event  of a termination,  the 
reason(s) for termination should be specified and, if clinically possible, the structural 
integrity of the terminated fetus should be assessed by [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomaly and the findings are 
reported).  
Abnormal  pregnancy  outcomes  are considered  SAEs.  If the outcome  of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomaly in a live -born baby, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  59  
 for reporting  SAEs.  Additional  information  about  pregnancy  outcomes  that are reported  to 
[COMPANY_007] Safety as SAEs follows:  
• Spontaneous  abortion  including  miscarriage  and missed  abortion  should  be reported 
as an SAE;  
• Neonatal  deaths  that occur  within  [ADDRESS_1121857] 
to causality, as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly related to 
exposure to the study intervention.  
Additional information regarding the EDP may be requested by [CONTACT_456]. Further 
follow -up of birth outcomes will be handled on a case -by-case basis (eg, follow -up on 
preterm infants to identify developmental delays). In the case of paternal exposure, the 
investigator  will provide  the participant  with the Pregnant  Partner  Release  of Information  
Form to deliver to his partner. The investigator must document in the source documents that 
the participant  was given  the Pregnant  Partner  Release  of Information  Form  to provide  to his 
partner.  
[IP_ADDRESS].  Exposure During Breastfeeding  
An EDB  occurs  if: 
• A female  participant  is found  to be breastfeeding  while  receiving  or after 
discontinuing study intervention.  
• A female  nonparticipant  is found  to be breastfeeding  while  being  exposed  or having 
been exposed to study intervention (ie, environmental exposure). An example of 
environmental EDB is a female family member or healthcare provider who reports 
that she is breastfeeding after having been exposed to the study intervention by 
[CONTACT_78262], inhalation, or skin contact.  
The investigator must report EDB to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The information must be reported 
using  the CT SAE  Report  Form.  When  EDB  occurs  in the setting  of environmental  exposure, 
the exposure information does not pertain to the participant enrolled in the study , so the 
information is not recorded on a CRF. However, a copy of the completed CT SAE Report 
Form is maintained in the investigator site file.  
An EDB report is not created when a [COMPANY_007] drug specifically approved for use in 
breastfeeding women (eg, vitamins) is administered in accordance with authorized use. 
However,  if the infant  experiences  an SAE  associated  with such a drug,  the SAE  is reported 
together with the EDB.  
[IP_ADDRESS].  Occupational Exposure  
The investigator  must  report  any instance  of occupational  exposure  to [COMPANY_007]  Safety  within  24 
hours of the investigator’s awareness using the CT SAE Report Form regardless of whether  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  60  
 there  is an associated  SAE.  Since  the information  about  the occupational  exposure  does not 
pertain to a participant enrolled in the study, the information is not recorded on a CRF; 
however, a copy of the completed CT SAE Report Form must be maintained in the 
investigator site file.  
8.4.6.  Cardiovascular  and Death  Events  
Not applicable.  
8.4.7.  Disease -Related  Events  and/or  Disease -Related  Outcomes  Not Qualifying  as AEs 
or SAEs  
Not applicable.  
8.4.8.  Adverse  Events  of Special  Interest  
AESIs are examined as part of routine safety data review procedures throughout the clinical 
trial and as part of signal detection processes. Should an aggregate analysis indicate that 
these  prespecified  events  occur  more  frequently  than expected,  eg, based  on epi[INVESTIGATOR_227924], literature, or other data, then this will be submitted and reported in accordance with 
[COMPANY_007]’s safety reporting requirements. Aggregate analyses of safety data will be performed 
on a regular basis per internal SOP.  
All AESIs must be reported as an AE or SAE following the procedures described in 
Section  8.4.[ADDRESS_1121858] SAE Report Form.  
[IP_ADDRESS].  Lack  of Efficacy  
This section  is not applicable  because  efficacy  is not expected  in the study  population.  
8.4.9.  Medical  Device  Deficiencies  
Not applicable.  
8.4.10.  Medication  Errors  
Medication errors may result from the administration or consumption of the study 
intervention  by [CONTACT_219892],  or at the wrong  time,  or at the wrong  dosage  strength.  
Medication  errors  are recorded  and reported  as follows:  
 
Recorded on the 
Medication  Error  Page 
of the CRF  Recorded on the 
Adverse  Event  Page 
of the CRF  Reported on the CT SAE 
Report Form to [COMPANY_007] 
Safety  Within  24 Hours  of 
Awareness  
All (regardless  of whether 
associated with an AE)  Any AE or SAE  associated 
with the medication error  Only  if associated  with an 
SAE 
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  61  
 CCI Medication  errors  include:  
• Medication  errors  involving  participant  exposure  to the study  intervention;  
• Potential  medication  errors  or uses outside  of what  is foreseen  in the protocol  that do 
or do not involve the study participant.  
Such  medication  errors  occurring  to a study  participant  are to be captured  on the medication 
error page of the CRF, which is a specific version of the AE page.  
Whether or not the medication error is accompanied by [CONTACT_1149], as determined by [CONTACT_1275],  the medication  error  is recorded  on the medication  error  page  of the CRF  and, if 
applicable,  any associated  AE(s),  serious  and nonserious,  are recorded  on the AE page  of the 
CRF.  
In the event of a medication dosing error, the sponsor should be notified  within [ADDRESS_1121859] SAE  Report 
Form only when associated with an SAE.  
8.5. Pharmacokinetics  
Blood samples of approximately 2 mL, to provide approximately 0.5 mL plasma, will be 
collected  for measurement  of plasma  concentrations  of PF-06821497  as specified  in the SoA. 
Instructions for the collection and handling of biological samples will be provided in the 
laboratory manual or by [CONTACT_456]. The actual date and time (24 -hour clock time) of each 
sample will be recorded.  
The actual times may change, but the number of samples will remain the same. All efforts 
will be made  to obtain  the samples  at the exact  nominal  time relative  to dosing.  Collection  of 
samples up to and including  C  hours after dose administration that are obtained within  
10% of the nominal  time relaCtiIve to dosing  (eg, within  6 minutes  of a 60 -minute  sample)  will 
not be captured  as a protocol  deviation,  as long as the exact  time of the collection  is noted  on 
the source document and the CRF. Collection of samples more than  C  hours after dose 
administration  that are obtained  ≤[ADDRESS_1121860]  time of the collection  is noted  on 
the source document and the CRF.  
Samples will be used to evaluate the PK of PF -06821497. Samples collected for analyses of 
PF-06821497  concentration  may also be used to evaluate  safety  or efficacy  aspects  related  to 
concerns arising during or after the study, for metabolite identification and/or evaluation of 
the bioanalytical method, or for other internal exploratory purposes.  
 
PF-[ADDRESS_1121861] be processed  and shipped  as indicated  in the instructions  provided to 
the investigator site to maintain sample integrity. Any deviations from the PK sample 
handling  procedure  (eg, sample  collection  and processing  steps,  interim  storage  or shippi[INVESTIGATOR_15889]), including any actions taken, must be documented and reported to the sponsor. 
On a case -by-case basis, the sponsor may make a determination as to whether sample 
integrity has been compromised.  
Any changes  in the timing  or addition  of time points  for any planned  study  assessments  must 
be documented and approved by [CONTACT_372011], but will not constitute a protocol amendment. The IRB/EC will 
be informed of any safety issues that require alteration of the safety monitoring scheme or 
amendment of the ICD.  
 
 
 
 
 
 
 
 
 
 
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  63  
 8.8. Immunogenicity  Assessments  
Immunogenicity  assessments  are not included  in this study.  
8.9. Health  Economics  
Health  economics/medical  resource  utilization  and health  economics  parameters  are not 
evaluated in this study.  
9. STATISTICAL  CONSIDERATIONS  
Detailed  methodology  for summary  and statistical  analyses  of the data collected  in this study 
is outlined here and further detailed in the SAP, which will be maintained by [CONTACT_456].  
The SAP may modify  what  is outlined  in the protocol  where  appropriate;  however,  any major 
modifications of the primary endpoint definitions or their analyses will also be reflected in a 
protocol amendment.  
9.1. Statistical Hypotheses  
There  are no statistical  hypotheses  for this study.  
9.2. Analysis Sets 
For purposes  of analysis,  the following  analysis  sets are defined:  
 
Participant  Analysis 
Set Description  
Enrolled  “Enrolled” means a participant’s, or their legally authorized 
representative’s, agreement to participate in a clinical study 
following completion of the informed consent process and 
assignment to study intervention. A participant will be 
considered  enrolled  if the informed  consent  is not withdrawn 
prior to participating in any study activity after screening.  
Potential participants who are screened for the purpose of 
determining  eligibility  for the study,  but do not participate  in 
the study, are not considered enrolled, unless otherwise 
specified by [CONTACT_760].  
PK Concentration 
Population  The PK concentration  population  is defined  as all participants 
randomized and treated who have at least [ADDRESS_1121862] they actually received.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  64  
 9.3. Statistical Analyses  
The SAP will be developed and finalized before any analyses are performed and will 
describe  the analyses  and procedures  for accounting  for missing,  unused,  and spurious  data. 
This section is a summary of the planned statistical analyses of the primary and secondary 
endpoints.  
9.3.1.  Pharmacokinetic  Analysis  
[IP_ADDRESS].  Derivation  of Pharmacokinetic  Parameters  
Plasma PK parameters of PF -06821497 will be derived (as data permits) from the 
concentration -time data using standard noncompartmental methods as outlined in Table 3. 
The PF -06821497 plasma PK parameters will be summarized descriptively by [CONTACT_75891]. 
Plasma concentrations will be listed and summarized descriptively by [CONTACT_75891], and 
nominal  PK sampling  time.  Individual  participant  and summary  profiles  (mean  and median 
plots)  of the plasma  concentration  time data will be plotted  using  actual  and nominal  times, 
respectively.  
Actual  PK sampling  times  will be used in the derivation  of PK parameters.  In the case that 
actual PK sampling times are not available, nominal PK sampling time will be used in the 
derivation of PK parameters.  
 
Table  3.  Plasma  PF-06821497  PK Parameters Definitions  
 
Parameter  Definition  Method  of Determination  
AUC inf* area under  the concentration -time curve  from  time 
[ADDRESS_1121863] + (Clast*/k el), 
where C last* is the predicted plasma 
concentration at the last quantifiable 
time point from the log -linear 
regression analysis and k el is the 
terminal  phase  rate constant  calculated 
by a linear regression of the loglinear  
concentration -time curve  
AUC last area under  the concentration -time curve  from  [ADDRESS_1121864] measurable concentration  Linear/Log  trapezoidal  method.  
Cmax maximum  observed  concentration  Observed  directly  from  data 
CCI   
   
       
      
  
   
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  65  
 CCI 9.3.2.  Statistical  Methods  for PK Data 
Part 1:  
Natural log transformed AUC inf (if data permit), AUC last and C max will be analyzed using a 
mixed effects model with sequence, period and treatment as fixed effects and participant 
within sequence as a random effect.  Estimates of the adjusted mean differences (Test - 
Reference) and corresponding 90% confidence intervals will be obtained from the model. 
The adjusted mean differences and 90% confidence intervals for the differences will be 
exponentiated  to provide  estimates  of the ratio of adjusted  geometric  means  (Test/Reference) 
and 90% confidence intervals for the ratios. Treatment A (CCI  formulation (Formulation 1) 
CCI mg (CCI ) fasted) will be the Reference treatment and Treatment B (CCI  
formulation (Formulation 2)  CCI mg CCI  mg) fasted) will be the Test treatment.  
Natural log transformed AUC inf (if data permit), AUC last and C max will be analyzed using a 
mixed effects model with sequence and treatment as fixed effects and participant within 
sequence as a random effect.  Estimates of the adjusted mean differences (Test -Reference) 
and corresponding 90% confidence intervals will be obtained from the model.  The adjusted 
mean differences and 90% confidence intervals for the differences will be exponentiated to 
provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% 
confidence intervals for the ratios. Treatment A (CCI  formulation (Formulation 1)  CCI mg 
CCI  mg) fasted) will be the Reference treatment and Treatment C (CCI  formulation 
(Formulation 3)  CCI mg CCI   mg; larger API [INVESTIGATOR_811018]) fasted) will be the Test 
treatment . For the second comparison, Treatment B (CCI  formulation (Formulation 2)  CCI 
mg CCI   mg) fasted)  will be the Reference  treatment  and Treatment  C (CCI  formulation 
(Formulation 3) CCI mg CCI  mg; larger API [INVESTIGATOR_811018]) fasted) will be the Test 
treatment.  
Part  2: 
Natural  log transformed  AUC inf (if data permit),  AUC last and Cmax will be analyzed  using  a 
mixed effects model with treatment as a fixed effect and participant as a random effect.  
Estimates of the adjusted mean differences (Test -Reference) and corresponding 90% 
confidence intervals will be obtained from the model.  The adjusted mean differences and 
90% confidence  intervals  for the differences  will be exponentiated  to provide  estimates  of the 
ratio of adjusted geometric means (Test/Reference) and 90% confidence intervals for the 
ratios. Treatment D (CCI  formulation (Formulation 2)  CCI  mg (CCI  mg) fasted) will be 
the Reference treatment and Treatments E and F (CCI  formulation (Formulation 2)  CCI  mg 
CCI  mg) fed: low -fat meal and CCI  formulation (Formulation 2) CCI  mg mg) 
fed: high -fat meal) will be the Test treatments.  
9.3.3.  Other  Safety  Analyses  
All safety  analyses  will be performed on the safety  population.  
AEs,  ECGs,  BP, PR, RR, and safety  laboratory  data will be reviewed  and summarized  on an 
ongoing  basis  during  the study  to evaluate  the safety  of participants.  Any clinical  laboratory, 
ECG, BP, RR and PR abnormalities of potential clinical concern will be described. Safety  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  66  
 data will be presented  in tabular  and/or  graphical  format  and summarized  descriptively, 
where appropriate.  
Medical history and physical examination and neurological examination information, as 
applicable,  collected  during  the course  of the study, will  be considered  source  data and will 
not be required to be reported, unless otherwise noted. However, any untoward findings 
identified on physical and/or neurological examinations conducted during the active 
collection period will be captured as AEs, if those findings meet the definition of an AE. 
Data  collected  at screening  that are used for inclusion/exclusion  criteria,  such as laboratory 
data, ECGs, and vital signs, will be considered source data, and will not be required to be 
reported,  unless  otherwise  noted.  Demographic  data collected  at screening  will be reported.  
CCI  
 
9.4. Interim  Analyses  
No formal  interim  analysis  will be conducted  for this study. As  this is an open -label  
study, the sponsor may  conduct unblinded reviews of the data during the course of the study 
for the purpose  of safety  assessment,  facilitating  PK/PD  modeling,  and/or  supporting  clinical 
development.  
9.5. Sample Size Determination  
Part  1: Sample  size of 12 participants  will provide  adequate  precision  of 90% CIs. The width 
of 90% confidence interval for different estimated effects is presented in Table 4.  
 
Table 4.  Expected  Widths  of the 90%  CIs for Different  Possible  Estimated 
Effects and Parameters of Interest for Part [ADDRESS_1121865] 
(100*Test/Reference)  90%CI  CI Width  
AUC  85% 74.74%  to 96.67%  21.94%  
 90% 79.13%  to 102.36%  23.23%  
 95% 83.53%  to 108.05%  24.52%  
 100%  87.93%  to 113.73%  25.81%  
 105%  92.32%  to 119.42%  27.10%  
 110%  96.72%  to 125.11%  28.39%  
 115%  101.11%  to 130.79%  29.68%  
Cmax 85% 68.01%  to 106.24%  38.23%  
 90% 72.01%  to 112.49%  40.48%  
 95% 76.01%  to 118.74%  42.73%  
 100%  80.01%  to 124.99%  44.98%  
 105%  84.01%  to 131.24%  47.23%  
 110%  88.01%  to 137.49%  49.48%  
 115%  92.01%  to 143.74%  51.73%  
PF-[ADDRESS_1121866]  deviations  of CCI  
for log e AUC inf and log e Cmax, respectively,  as obtained  from  study  C2321001.  
Part 2: Sample size of 6 participants will provide adequate precision of 90% CIs. The 
following  table  presents  the width  of 90% confidence  interval  for different  estimated  effects:  
 
Table 5.  Expected  Widths  of the 90%  CIs for Different  Possible  Estimated 
Effects and Parameters of Interest for Part [ADDRESS_1121867] 
(100*Test/Reference)  90%CI  CI Width  
AUC   CCI 
 
 
 
 
CCI         
       
       
       
       
Cmax        
        
        
        
        
These  calculations  are based  on the estimates  of within -subject  standard  deviations  of CCI  
for log e AUC inf and log e Cmax,, respectively,  as obtained  from  study  C2321001.  
Participants  who withdraw  from  the study  may be replaced  at the discretion  of the 
investigator upon consultation with the sponsor.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  68  
 10. SUPPORTING  DOCUMENTATION  AND  OPERATIONAL  CONSIDERATIONS  
10.1. Appendix  1: Regulatory,  Ethical,  and Study  Oversight  Considerations  
10.1.1.  Regulatory  and Ethical  Considerations  
This study  will be conducted in accordance with the protocol and with the following:  
• Consensus  ethical  principles  derived  from  international  guidelines,  including  the 
Declaration of Helsinki and CIOMS International Ethical Guidelines;  
• Applicable  ICH GCP  guidelines;  
• Applicable  laws and regulations,  including  applicable  privacy  laws.  
The protocol,  protocol  amendments,  ICD,  SRSD(s),  and other  relevant  documents  
(eg, advertisements)  must  be reviewed  and approved  by [CONTACT_456],  submitted  to an IRB/EC 
by [CONTACT_093], and reviewed and approved by [CONTACT_1201]/EC before the study is initiated.  
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes  made  to the study  design,  except  for changes  necessary  to eliminate  an immediate 
hazard to study participants.  
Protocols and any substantial amendments to the protocol will require health authority 
approval  prior  to initiation  except  for changes  necessary  to eliminate  an immediate  hazard  to 
study participants.  
The investigator  will be responsible  for the following:  
• Providing  written  summaries  of the status  of the study  to the IRB/EC  annually  or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/EC;  
• Notifying  the IRB/EC  of SAEs  or other  significant  safety  findings  as required  by 
[CONTACT_1744]/EC procedures;  
• Providing oversight of the conduct of the study at the site and adherence to 
requirements  of 21 CFR,  ICH GCP guidelines,  the IRB/EC,  European  regulation 
536/2014  for clinical  studies,  European  Medical  Device  Regulation  2017/745  for 
clinical device research, and all other applicable local regulations.  
[IP_ADDRESS].  Reporting  of Safety  Issues  and Serious  Breaches  of the Protocol  or ICH  GCP  
In the event  of any prohibition  or restriction  imposed  (ie, clinical  hold)  by [CONTACT_22844], or if the investigator is aware of any new 
information that might influence the evaluation of the benefits and risks of the study 
intervention, [COMPANY_007] should be informed immediately.  
PF-[ADDRESS_1121868],  and 
of any serious breaches of this protocol or of the ICH GCP guidelines that the investigator 
becomes aware of.  
10.1.2.  Financial Disclosure  
Not applicable.  
10.1.3.  Informed  Consent  Process  
The investigator or the investigator’s representative will explain the nature of the study, 
including the risks and benefits, to the participant and answer all questions regarding the 
study.  The participant  should  be given  sufficient  time and opportunity  to ask questions  and to 
decide whether or not to participate in the trial.  
Participants must be informed that their participation is voluntary. Participants will be 
required  to sign a statement  of informed  consent  that meets  the requirements  of 21 CFR  50, 
local regulations, ICH guidelines, privacy and data protection requirements, where 
applicable, and the IRB/EC or study center.  
The investigator must ensure that each participant is fully informed about the nature and 
objectives  of the study,  the sharing  of data related  to the study,  and possible  risks  associated 
with participation, including the risks associated with the processing of the participant’s 
personal data.  
The participant  must  be informed  that their personal  study -related  data will be used by [CONTACT_219897]. The level  of disclosure  must  also be 
explained to the participant.  
The participant  must  be informed  that their medical  records  may be examined  by [CONTACT_11000], by 
[CONTACT_6667]/EC members, and by [CONTACT_6668].  
The investigator  further  must  ensure  that each study  participant  is fully  informed  about  their 
right to access and correct their personal data and to withdraw consent for the processing of 
their personal data.  
The medical record must include a statement that written informed consent was obtained 
before  the participant  was enrolled  in the study  and the date on which  the written  consent  was 
obtained. The authorized person obtaining the informed consent must also sign the ICD.  
Participants  must  be reconsented  to the most  current  version  of the IRB/EC -approved ICD(s) 
during their participation in the study as required per local regulations.  
A copy  of the ICD(s) must  be provided to the participant.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  70  
 A participant  who is rescreened  is not required  to sign another  ICD if the rescreening  occurs 
within 10 days from the previous ICD signature [CONTACT_568].  
10.1.4.  Data  Protection  
All parties  will comply  with all applicable  laws,  including  laws regarding  the implementation 
of organizational and technical measures to ensure protection of participant data.  
Participants’  personal  data will be stored  at the study  site in encrypted  electronic  and/or  paper 
form and will be password protected or secured in a locked room to ensure that only 
authorized study staff have access. The study site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster. In the event of a potential personal data breach, the study  site will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifications as required by [CONTACT_2371].  
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any 
participant  records  or data sets that are transferred  to the sponsor  will contain  the numerical 
code; participant names will not be transferred.  All other  identifiable data transferred  to the 
sponsor will be identified by [CONTACT_20007], participant -specific code. The study site will 
maintain a confidential list of participants who participated in the study, linking each 
participant’s numerical code to their actual identity and medical record ID. In case of data 
transfer,  the sponsor  will protect  the confidentiality  of participants’  personal  data consistent 
with the clinical study agreement and applicable privacy laws.  
Information  technology  systems  used to collect,  process,  and store  study -related  data are 
secured by [CONTACT_46387], alteration, or unauthorized disclosure or access.  
The sponsor  maintains  standard  operating  procedures  on how to respond  in the event  of 
unauthorized access, use, or disclosure of sponsor information or systems.  
10.1.5.  Committees  Structure  
[IP_ADDRESS].  Data  Monitoring  Committee  
This study  will not use an E -DMC.  
10.1.6.  Dissemination  of Clinical  Study  Data  
[COMPANY_007] fulfills its commitment to publicly disclose clinical study results through posting the 
results of studies on www.clinicaltrials.gov  (ClinicalTrials.gov), the EudraCT/CTIS, and/or 
www.pfizer.com,  and other  public  registries  and websites  in accordance  with applicable  local 
laws/regulations. In addition, [COMPANY_007] reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  71  
 In all cases, study results are reported by [CONTACT_4715], accurate, balanced, and 
complete  manner  and are reported  regardless  of the outcome  of the study  or the country  in 
which the study was conducted.  
www.clinicaltrials.gov  
[COMPANY_007]  posts  clinical  trial results  on www.clinicaltrials.gov  for [COMPANY_007] -sponsored  interventional 
studies (conducted in patients) that evaluate the safety and/or efficacy of a product,  
regardless of the geographical location in which the study is conducted. These results are 
submitted for posting in accordance with the format and timelines set forth by [CONTACT_20008].  
EudraCT/CTIS  
[COMPANY_007]  posts  clinical  trial results  on EudraCT/CTIS  for [COMPANY_007] -sponsored  interventional  studies 
in accordance with the format and timelines set forth by [CONTACT_20009].  
www.pfizer.com  
[COMPANY_007]  posts  CSR  synopses  and plain -language  study  results  summaries  on www.pfizer.com  
for [COMPANY_007] -sponsored interventional studies at the same time the  corresponding study  results 
are posted to www.clinicaltrials.gov.  CSR synopses will have personally identifiable 
information anonymized.  
Documents  within  marketing  applications  
[COMPANY_007]  complies  with applicable  local  laws/regulations  to publish  clinical  documents  included 
in marketing applications. Clinical documents include summary documents and CSRs 
including the protocol and protocol amendments, sample CRFs, and SAPs. Clinical 
documents will have personally identifiable information anonymized.  
Data  sharing  
[COMPANY_007] provides researchers secure access to participant -level data or full CSRs for the 
purposes  of “bona -fide scientific  research”  that contributes  to the scientific  understanding  of 
the disease, target, or compound class. [COMPANY_007] will make data from these trials available  
[ADDRESS_1121869], including individuals 
requesting access for commercial/competitive or legal purposes.  
10.1.7.  Data Quality Assurance  
All participant  data relating  to the study  will be recorded  on printed  or electronic  CRF  unless 
transmitted  to the sponsor  or designee  electronically  (eg, laboratory  data).  The investigator  is 
PF-[ADDRESS_1121870]  ensure  that the CRFs  are securely  stored  at the study  site in encrypted 
electronic and/or paper form and are password -protected or secured in a locked room to 
prevent access by [CONTACT_20011].  
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory agency inspections and provide direct access to source data documents. This 
verification  may also occur  after study  completion.  It is important  that the investigator(s)  and 
their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.  
Monitoring details describing strategy, including definition of study -critical data items and 
processes  (eg, risk-based  initiatives  in operations  and quality,  such as risk management  and 
mitigation strategies and analytical risk -based monitoring), methods, responsibilities, and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual, or on -site monitoring), are provided in the data management plan and/or 
IQMP maintained and utilized by [CONTACT_36613].  
The sponsor  or designee  is responsible  for the data management  of this study,  including 
quality checking of the data.  
Records and documents, including signed ICDs, pertaining to the conduct of this study must 
be retained by [CONTACT_1732] [ADDRESS_1121871]  ensure  that the records  continue  to be stored  securely  for as long as they are 
maintained.  
When  participant  data are to be deleted,  the investigator  will ensure  that all copi[INVESTIGATOR_219854].  
The investigator(s) will notify the sponsor or its agents immediately of any regulatory 
inspection notification in relation to the study. Furthermore, the investigator will cooperate 
with the sponsor  or its agents  to prepare  the investigator  site for the inspection  and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly resolve any discrepancies that are identified 
between the study data and the participant’s medical records. The investigator will promptly 
provide copi[INVESTIGATOR_19946]. Before response 
submission to the regulatory authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to any such findings.  
PF-[ADDRESS_1121872] be available at 
the investigative  site that identifies  those  data that will be recorded  on the CRF  and for which 
the CRF will be the source document.  
Definition  of what  constitutes  source  data and its origin  can be found  in the Source 
Document Locator, which is maintained by [CONTACT_456]’s designee ([COMPANY_007] CRU).  
Description  of the use of the computerized  system  is documented  in Source  Document 
Locator, which is maintained by [CONTACT_456]’s designee ([COMPANY_007] CRU).  
The investigator  must  maintain  accurate  documentation  (source  data)  that supports  the 
information entered in the CRF.  
The sponsor  or designee  will perform  mornitoring  to confirm  that data entered  into the CRF 
by [CONTACT_1191], complete, and verifiable from source documents; 
that the safety and rights of participants are being protected; and that the study is being 
conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP guidelines, and all applicable regulatory requirements.  
10.1.9.  Study and Site Start and Closure  
The study  start date is the date on which  the clinical  study  will be open  for recruitment  of 
participants.  
The first act of recruitment  is the date of the first participant’s  first visit and will be the study 
start date.  
The sponsor designee reserves the right to close the study  site or terminate the study  at any 
time for any reason at the sole discretion of the sponsor, including (but not limited to) 
regulatory authority decision, change in opi[INVESTIGATOR_1100]/EC, or change in benefit -risk 
assessment. Study sites will be closed upon study completion. A study site is considered 
closed  when  all required  documents  and study  supplies  have  been  collected  and a study -site 
closure visit has been performed.  
The investigator  may initiate  study -site closure  at any time upon  notification  to the sponsor  if 
requested  to do so by [CONTACT_22846]/EC or if such termination is  required to protect the 
health of study participants.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  74  
 Reasons  for the early  closure  of a study  site by [CONTACT_219900]: 
• Failure  of the investigator  to comply  with the protocol,  the requirements  of the 
IRB/EC or local health authorities, the sponsor’s procedures, or the ICH GCP 
guidelines;  
• Inadequate  recruitment of  participants by  [CONTACT_093];  
• Discontinuation of further study  intervention development.  
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators,  the ECs/IRBs,  the regulatory  authorities,  and any CRO(s)  used in the study  of 
the reason for termination or suspension, as specified by [CONTACT_56859]. The investigator shall promptly inform the participant and should assure 
appropriate participant therapy and/or follow -up. 
Study  termination  is also provided  for in the clinical  study  agreement.  If there  is any conflict 
between the contract and this protocol, the contract will control as to termination rights.  
10.1.10.  Publication  Policy  
For multicenter trials, the primary publication will be a joint publication developed by [CONTACT_219901](s)  of the study  covering  all study  sites. 
The investigator agrees to refer to the primary publication in any subsequent publications.  
[COMPANY_007] will not provide any financial compensation for the investigator’s  participation in the 
preparation  of the primary  congress  abstract,  poster,  presentation,  or primary  manuscript  for 
the study.  
Investigators are free to publish individual center results that they deem to be clinically 
meaningful after publication of the overall results of the study or [ADDRESS_1121873]  to the other 
requirements described in this section.  
The investigator will provide [COMPANY_007] an opportunity to review any proposed publication or  
any other type of disclosure of the study results (collectively, “publication”) before it is 
submitted or otherwise disclosed and will submit all publications to [COMPANY_007] [ADDRESS_1121874], remove any previously undisclosed 
confidential information before disclosure, except for any study intervention or  [COMPANY_007] - 
related information necessary for the appropriate scientific presentation or understanding of 
the study results.  For joint publications, should there be disagreement regarding 
interpretation  and/or  presentation  of specific  analysis  results, resolution of, and responsibility 
for, such disagreements will be the collective responsibility of all authors of the publication.  
PF-[ADDRESS_1121875] 
access to the relevant statistical tables, figures, and reports (in their original format) required 
to develop the publication.  
10.1.11.  Sponsor’s  Medically  Qualified  Individual  
The contact  [CONTACT_219902]’s  MQI  for the study  is documented  in the study 
contact [CONTACT_306925].  
To facilitate access to their investigator and the sponsor’s MQI for study -related medical 
questions  or problems  from  nonstudy  healthcare  professionals,  participants  are provided  with 
an ECC at the time of informed consent. The ECC contains, at a minimum, (a) protocol and 
study intervention identifiers, (b) participant’s study identification number, (c) site 
emergency phone number active 24 hours/day, [ADDRESS_1121876], the established communication pathways 
between  the participant  and their investigator and site  staff,  and between  the investigator  and 
sponsor study team. The ECC is only  to be used by [CONTACT_219904],  as a means  of reaching  the investigator  or site staff related  to the care of a 
participant.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  76  
 10.2. Appendix  2: Clinical  Laboratory  Tests  
The following  safety  laboratory  tests will be performed  at times  defined  in the SoA section  of 
this protocol. Additional laboratory results may be reported on these samples as a result of  
the method of analysis or the type of analyzer used by [CONTACT_20019], or as derived 
from calculated values. These additional tests would not require additional collection of 
blood.  Unscheduled  clinical  laboratory  measurements  may be obtained  at any time during  the 
study to assess any perceived safety issues.  
Table 6. Protocol -Required  Safety  Laboratory  Assessments  
 
Hematology  Chemistry  Urinalysis  Other  
Hemoglobin 
Hematocrit 
RBC count 
Platelet  count 
WBC count  
Total  neutrophils  (Abs) 
Eosinophils (Abs) 
Monocytes (Abs) 
Basophils (Abs) 
Lymphocytes (Abs)  Urea and creatinine 
CystatinC  and eGFR 
Glucose (fasting) 
Calcium  
Sodium 
Potassium 
Chloride  
Total  CO 2 (bicarbonate) 
AST, ALT  
Total bilirubin 
Alkaline  phosphatase 
Uric acid  
Albumin 
Total  protein  Local  dipstick:  
pH 
Glucose  (qual) 
Protein (qual) 
Blood (qual) 
Ketones 
Nitrites  
Leukocyte  esterase  
Laboratory:  
Microscopy  and 
culturea • Urine  cotinine  
• Pregnancy  test (β-hCG)d 
• PT, PTT,  INR 
 
 
At screening:  
• FSHb 
• Urine  drug screeningc 
• Hepatitis  B surface 
antigen  
• Hepatitis  C antibody  
• Hepatitis  B core antibody  
• HIV 
 For suspected  DILIe: 
AST/ALT  
T bili, direct  and indirect 
bili 
Total bile acids, GGT 
Total  protein,  albumin 
CK 
PT, INR 
Acetaminophen/paracetamol 
or 
protein adduct levels 
Hepatitis  serology  (even  if 
screening negative)    
 For suspected  DICI/DIKIf: 
Creatinine (Scr)  
CystatinC (Scys) 
eGFR (Scr only and 
combined  Scr+Scys)    
 Spot (dipstick)  UACR    
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  77  
 Table 6. Protocol -Required  Safety  Laboratory  Assessments  
 
Hematology  Chemistry  Urinalysis  Other  
a. Only  if UTI is suspected  and urine  dipstick  is positive  for nitrites  or leukocyte  esterase  or both.  
b. For confirmation  of postmenopausal  status  only.  
c. The minimum  requirement  for drug screening  includes  cocaine,  THC,  opi[INVESTIGATOR_858]/opi[INVESTIGATOR_2438],  benzodiazepi[INVESTIGATOR_1651], 
and amphetamines (others are site and study specific).  
d. Local  urine  testing  will be standard  for the protocol  unless  serum  testing  is required  by [CONTACT_770461]/EC. Serum or urine -hCG for female participants of childbearing potential.  
e. See Appendix  [ADDRESS_1121877]  any 
clinically relevant changes occurring during the study in the AE section of the CRF.  
Any remaining serum/plasma from samples collected for clinical safety laboratory 
measurements  at baseline  and at all times  after dose administration  may be retained  and 
stored for the duration of the study.  CCI 
 
These  data will not be included  in the CSR.  Samples  to be used for this 
purpose will be shipped to either a [COMPANY_007] -approved BBS facility or other designated 
laboratory and retained for up to 1 year following the completion of the study.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  78  
 10.3. Appendix  3: Adverse  Events:  Definitions  and Procedures  for Recording, 
Evaluating, Follow -Up, and Reporting  
10.3.1.  Definition of AE 
 
AE Definition  
• An AE is any untoward medical occurrence in a patient or clinical study 
participant,  temporally  associated  with the use of study  intervention,  whether  or not 
considered related to the study intervention.  
• Note:  An AE can therefore  be any unfavorable  and unintended  sign (including  an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) 
temporally associated with the use of study intervention.  
 
 
Events  Meeting  the AE Definition  
• Any abnormal  laboratory  test results  (hematology,  clinical  chemistry,  or urinalysis) 
or other  safety  assessments  (eg, ECG,  radiological  scans,  vital sign measurements), 
including those that worsen from baseline, considered clinically significant in the 
medical and scientific judgment of the investigator. Any abnormal laboratory test 
results that meet any of the conditions below must be recorded as an AE:  
• Is associated  with accompanying  symptoms;  
• Requires  additional  diagnostic  testing  or medical/surgical  intervention;  
• Leads  to a change  in study  dosing  (outside  of any protocol -specified  dose 
adjustments) or discontinuation from the study, significant additional 
concomitant drug treatment, or other therapy.  
• Exacerbation  of a chronic  or intermittent  preexisting  condition,  including  an 
increase in either frequency and/or intensity of the condition.  
• New  condition  detected  or diagnosed  after study  intervention  administration,  even 
though it may have been present before the start of the study.  
• Signs,  symptoms,  or the clinical  sequelae  of a suspected  drug-drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention  or a concomitant  medication.  Overdose  per se will not be reported  as 
an AE or SAE unless it is an intentional overdose taken with possible 
suicidal/self -harming intent. Such overdoses should be reported regardless of 
sequelae.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  79  
  
Events  NOT  Meeting  the AE Definition  
• Any clinically  significant abnormal laboratory  findings or other abnormal safety 
assessments  that are associated  with the underlying  disease,  unless  judged  by [CONTACT_11009]’s condition.  
• The disease/disorder  being  studied  or expected  progression,  signs,  or symptoms  of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.  
• Medical  or surgical  procedure  (eg, endoscopy,  appendectomy):  the condition  that 
leads to the procedure is the AE.  
• Situations  in which  an untoward  medical  occurrence  did not occur  (social  and/or 
convenience admission to a hospi[INVESTIGATOR_307]).  
• Anticipated  day-to-day fluctuations  of preexisting  disease(s)  or condition(s)  present 
or detected at the start of the study that do not worsen.  
10.3.2.  Definition of an  SAE  
 
An SAE  is defined  as any untoward  medical  occurrence  that,  at any dose,  meets  one 
or more of the criteria listed below:  
a.  Results in  death  
b. Is life -threatening  
The term “life-threatening”  in the definition  of “serious”  refers  to an event  in which  the 
participant  was at risk of death  at the time of the event.  It does not refer  to an event  that 
hypothetically might have caused death if it were more severe.  
c.  Requires  inpatient  hospi[INVESTIGATOR_219855], hospi[INVESTIGATOR_12994] (usually 
involving  at least an overnight  stay)  at the hospi[INVESTIGATOR_371992]/or treatment that would not have been appropriate in the physician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious.  When  in doubt  as to whether  “hospi[INVESTIGATOR_059]” occurred or was necessary,  the 
AE should be considered serious.  
Hospi[INVESTIGATOR_54725] a preexisting  condition  that did not worsen 
from baseline is not considered an AE.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  80  
  
d. Results  in persistent  or significant disability/incapacity  
• The term disability  means  a substantial  disruption  of a person’s  ability  to conduct 
normal life functions.  
• This definition  is not intended  to include  experiences  of relatively  minor  medical 
significance, such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), that may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
e.  Is a congenital  anomaly/birth  defect  
f. Is a suspected  transmission  via a [COMPANY_007]  product  of an infectious  agent,  pathogenic 
or non -pathogenic  
The event  may be suspected  from  clinical  symptoms  or laboratory  findings  indicating 
an infection in a participant exposed to a [COMPANY_007] product. The terms “suspected 
transmission” and “transmission” are considered synonymous. These cases are 
considered unexpected and handled as serious expedited cases by [CONTACT_372014]. Such cases are also considered for reporting as product defects, if 
appropriate.  
g. Other situations:  
• Medical or scientific judgment should be exercised by [CONTACT_811044],  such as significant  medical 
events that may jeopardize the participant or may require medical or surgical 
intervention to prevent one of the other outcomes listed in the above definition. 
These events should usually be considered serious.  
• Examples  of such events  include  invasive  or malignant  cancers,  intensive  treatment 
in an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug 
dependency or drug abuse.  
10.3.3.  Recording/Reporting  and Follow -Up of AEs and/or  SAEs  During  the Active 
Collection Period  
 
AE and SAE Recording/Reporting  
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAEs on the CT SAE Report Form to [COMPANY_007] Safety throughout the active 
collection period. These requirements are delineated for 3 types of events: (1) SAEs; (2) 
nonserious  AEs;  and (3) exposure  to the study  intervention  under  study  during  pregnancy 
or breastfeeding, and occupational exposure.  
PF-[ADDRESS_1121878] SAE 
Report Form for reporting of SAE information.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* EDP (with or without an associated AE or SAE): any pregnancy information is reported to [COMPANY_007] 
Safety  using  the CT SAE  Report  Form  and EDP  Supplemental  Form;  if the EDP  is associated  with 
an SAE, then the SAE is reported to [COMPANY_007] Safety using the CT SAE Report Form.  
** EDB  is reported  to [COMPANY_007]  Safety  using  the CT SAE  Report  Form, which  would  also include  details 
of any SAE that might be associated with the EDB.  
*** Environmental  or occupational  exposure:  AEs or SAEs  associated  with occupational  exposure 
are reported to [COMPANY_007] Safety using the CT SAE Report Form.  
• When  an AE or SAE  occurs,  it is the responsibility  of the investigator  to review  all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostic 
reports) related to the event.  
• The investigator  will then record  all relevant  AE or SAE  information  in the CRF.  
• It is not acceptable  for the investigator  to send photocopi[INVESTIGATOR_219860]’s 
medical records to [COMPANY_007] Safety in lieu of completion of the CT SAE Report 
Form/AE or SAE CRF page.  Safety Event  Recorded  on the CRF  Reported on the CT SAE 
Report Form to [COMPANY_007] 
Safety  Within  24 Hours  of 
Awareness  
SAE All All 
Nonserious  AE All None  
Exposure to the study 
intervention  under  study 
during pregnancy or 
breastfeeding  All AEs/SAEs  associated 
with EDP or EDB  
 
Note: Instances of EDP or 
EDB  not associated  with an 
AE or SAE  are not captured 
in the CRF  All instances  of EDP  are 
reported  (whether  or not 
there is an associated 
SAE)*  
All instances  of EDB  are 
reported (whether or not 
there is an associated 
SAE)**  
Environmental or 
occupational  exposure  to 
the product under study 
to a nonparticipant (not 
involving EDP or EDB)  None.  Exposure  to a study 
non-participant is not 
collected on the CRF  The exposure  (whether  or 
not there is an associated 
AE or SAE) must be 
reported***  
 
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  82  
  
• There may be instances when copi[INVESTIGATOR_240802]. In this case, all participant identifiers, with the 
exception  of the participant  number,  will be redacted  on the copi[INVESTIGATOR_240803].  
• The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms,  and/or  other  clinical  information.  Whenever  possible,  the diagnosis  (not 
the individual signs/symptoms) will be documented as the AE or SAE.  
Assessment of Intensity  
The investigator  will make  an assessment  of intensity  for each AE and SAE  reported 
during the study and assign it to 1 of the following categories:  
• Mild: A type of AE that is usually transient and may require only minimal 
treatment  or therapeutic  intervention.  The event  does not generally  interfere  with 
usual ADL.  
• Moderate: A type of AE that is usually alleviated with additional specific 
therapeutic  intervention.  The event  interferes  with usual  ADL,  causing  discomfort, 
but poses no significant or permanent risk of harm to the research participant.  
• Severe:  A type of AE that interrupts  usual  ADL,  or significantly  affects  clinical 
status, or may require intensive therapeutic intervention.  
An event  is defined  as “serious”  when  it meets  at least 1 of the predefined  outcomes  as 
described in the definition of an SAE, NOT when it is rated as severe.  
 
 
Assessment of Causality  
• The investigator  is obligated  to assess  the relationship  between  study  intervention 
and each occurrence of each AE or SAE. The investigator will use clinical 
judgment to determine the relationship.  
• A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or  arguments  to suggest  a causal  relationship,  rather  than a relationship  cannot 
be ruled out.  
• Alternative  causes,  such as underlying  disease(s),  concomitant therapy,  and other 
risk factors,  as well as the temporal  relationship  of the event  to study  intervention 
administration, will be considered and investigated.  
• The investigator  will also consult  the IB and/or  product  information,  for marketed 
products, in their assessment.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  83  
  
• For each AE or SAE,  the investigator must  document  in the medical  notes  that they 
have reviewed the AE or SAE and have provided an assessment of causality.  
• There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every  event  before  the initial  transmission  of the SAE  data  to the sponsor . 
• The investigator  may change  theiropi[INVESTIGATOR_240804] -up 
information and send an SAE follow -up report with the updated causality 
assessment.  
• The causality  assessment  is one of the criteria  used when  determining  regulatory 
reporting requirements.  
• If the investigator does not know whether or not the study intervention caused the 
event,  then the event  will be handled  as “related  to study  intervention”  for reporting 
purposes, as defined by [CONTACT_456]. In addition, if the investigator determines that 
an SAE is associated with study procedures, the investigator must record this  
causal relationship in the source documents and CRF, and report such an 
assessment in the dedicated section of the CT SAE Report Form and in accordance 
with the SAE reporting requirements.  
 
 
Follow -Up of AEs and SAEs  
• The investigator  is obligated  to perform  or arrange  for the conduct  of supplemental 
measurements and/or evaluations, as medically indicated or as requested by [CONTACT_103], to elucidate the nature and/or causality of the AE or SAE as fully as 
possible. This may include additional laboratory tests or investigations, 
histopathological examinations, or consultation with other healthcare providers.  
• If a participant dies during participation in the study or during a recognized 
follow -up period,  the investigator  will provide  [COMPANY_007]  Safety  with a copy  of any 
postmortem findings, including histopathology.  
• New  or updated  information  will be recorded  in the originally  submitted 
documents.  
• The investigator  will submit  any updated  SAE  data to the sponsor  within  [ADDRESS_1121879]  
• The primary  mechanism  for reporting  an SAE  to [COMPANY_007]  Safety  will be the 
electronic DCT.  
• If the electronic  system  is unavailable,  then the site will use the paper  SAE  DCT 
(see next section) to report the event within 24 hours.  
• The site will enter  the SAE  data into the electronic  DCT  (eg, eSAE  or PSSA)  or 
paper form (as applicable) as soon as the data become available.  
• After  the study  is completed  at a given  site, the electronic  DCT  will be taken 
off-line to prevent the entry of new data or changes to existing data.  
• If a site receives  a report  of a new SAE  from  a study  participant  or receives  updated 
data on a previously  reported  SAE  after the electronic  DCT  has been  taken  off-line, 
then the site can report this information on a paper SAE form (see next section) or 
to [COMPANY_007] Safety by [CONTACT_756].  
 
 
SAE  Reporting  to [COMPANY_007]  Safety  via the CT SAE  Report  Form  
• Facsimile  transmission  of the CT SAE  Report  Form  is the preferred  method  to 
transmit this information to [COMPANY_007] Safety.  
• In circumstances  when  the facsimile  is not working,  an alternative  method  should 
be used, eg, secured (Transport Layer Security) or password -protected email. If 
none  of these  methods  can be used,  notification by [CONTACT_9337] a 
copy of the CT SAE Report Form sent by [CONTACT_22855].  
• Initial notification via telephone does not replace the need for the investigator to 
complete  and sign the CT SAE  Report  Form  pages  within  the designated  reporting 
time frames.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  85  
 10.4. Appendix  4: Contraceptive  and Barrier  Guidance  
10.4.1.  Male  Participant  Reproductive  Inclusion  Criteria  
Male  participants  are eligible  to participate  if they agree  to the following  requirements  during 
the intervention period and for at least [ADDRESS_1121880] dose of PF -06821497, which 
corresponds to the time needed to eliminate reproductive safety risk of the study 
intervention(s):  
• Refrain  from  donating  sperm. 
PLUS either : 
• Be abstinent  from  heterosexual  intercourse  as their preferred  and usual  lifestyle 
(abstinent on a long -term and persistent basis) and agree to remain abstinent.  
OR 
• Must  agree  to use contraception/barrier  as detailed  below:  
• Agree to use a male condom, and should also be advised of the benefit for a 
female  partner  to use a highly  effective  method  of contraception,  as a condom 
may break  or leak,  when  having  sexual  intercourse  with a WOCBP  who is not 
currently pregnant.  
• In addition  to male  condom  use, a highly  effective  method  of contraception  may be 
considered in WOCBP partners of male participants (refer to the list of highly 
effective methods below in Section 10.4.4 ). 
10.4.2.  Female  Participant  Reproductive  Inclusion  Criteria  
The criteria below are part of Inclusion Criterion 1 (Age and Sex; Section 5.1 ) and specify 
the reproductive  requirements  for including  female  participants.  Refer  to Section  10.4.[ADDRESS_1121881] of contraceptive methods permitted in the study.  
• A female participant is eligible to participate if she (a) is not pregnant or 
breastfeeding;  (b) agrees  to not donate  eggs (ova,  oocytes)  for the purpose  of reproduction  3 
months; and (c) at least 1 of the following conditions applies:  
• Is not a WOCBP (see definition in Section 10.4.3 ). 
• OR 
• Is a WOCBP who agrees to use a highly effective contraceptive method (failure rate 
of <1% per year) with low user dependency  during the intervention period and for at 
least [ADDRESS_1121882] dose of study  intervention,  which  corresponds  to the time 
needed to eliminate any reproductive safety risk of the study intervention(s). The  
PF-[ADDRESS_1121883] dose of study intervention.  
OR 
• Is a WOCBP and agrees to use a highly effective (failure rate of <1% per year) user- 
dependent  method of contraception during the intervention period and for at least [ADDRESS_1121884] dose of study  intervention,  which  corresponds  to the time needed 
to eliminate any reproductive safety risk of the study intervention(s). In addition to 
her use of the highly effective method above, she agrees to concurrently  use an 
effective barrier method. The investigator should evaluate the effectiveness of the 
contraceptive method in relationship to the first dose of study intervention.  
The investigator  is responsible  for reviewing  the woman’s  medical  history,  menstrual  history, 
and recent sexual activity in order to decrease the risk of enrolling a woman with an early, 
undetected pregnancy.  
10.4.3.  Woman  of Childbearing  Potential  
A woman  is considered  fertile  following  menarche  and until becoming  postmenopausal 
unless permanently sterile (see below).  
If fertility  is unclear  (eg, amenorrhea  in adolescents  or athletes)  and a menstrual  cycle  cannot 
be confirmed before the first dose of study intervention, additional evaluation should be 
considered.  
Women  in the following  categories  are not considered  WOCBP:  
1. Premenopausal  female  with 1 of the following:  
• Documented  hysterectomy;  
• Documented bilateral salpi[INVESTIGATOR_1656];  
• Documented  bilateral  oophorectomy.  
For individuals with permanent infertility due to a medical cause other than the above 
(eg, mullerian  agenesis,  androgen  insensitivity),  investigator  discretion  should  be applied 
to determining study entry.  
Note:  Documentation  for any of the above  categories  can come  from  the site personnel’s 
review of the participant’s medical records, medical examination, or medical history 
interview.  The method  of documentation  should  be recorded  in the participant’s  medical 
record for the study.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  87  
 2. Postmenopausal  female.  
• A postmenopausal  state is defined  as no menses  for 12 months  without  an 
alternative medical cause. In addition:  
• A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal  state in women  under  60 years  old and not using  hormonal 
contraception or HRT.  
• A female  on HRT  and whose  menopausal  status  is in doubt  will be required  to 
use one of the highly effective nonestrogen hormonal contraception methods 
if she wishes to continue her HRT during the study. Otherwise, she must 
discontinue  HRT  to allow  confirmation  of postmenopausal  status  before  study 
enrollment.  
10.4.4.  Contraception  Methods  
Contraceptive  use by [CONTACT_219910]/regulations 
regarding the use of contraceptive methods for those participating in clinical trials.  
The following  contraceptive  methods  are appropriate  for this study: 
Highly Effective Methods  That Have Low User Dependency  
1. Implantable  progestogenonly  hormone  contraception  associated  with inhibition  of 
ovulation.  
2. Intrauterine  device.  
3. Intrauterine  hormone -releasing  system.  
4. Bilateral  tubal  occlusion.  
5. Vasectomized  partner.  
• Vasectomized  partner  is a highly  effective  contraceptive  method  provided  that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed.  If not, an additional highly effective method of contraception 
should be used.  The spermatogenesis cycle is approximately 90 days.  
Highly  Effective  Methods  That Are User  Dependent  
6. Combined  (estrogen - and progestogen -containing)  hormonal  contraception  associated 
with inhibition of ovulation:  
• Oral + barrier*  
• Intravaginal  + barrier*  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  88  
 • Transdermal  + barrier*  
7. Progestogen -only hormone  contraception  associated  with inhibition  of ovulation:  
• Oral + barrier*  
• Injectable  + barrier*  
8. Sexual Abstinence  
9. Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention.  The reliability  of sexual  abstinence  needs  to be evaluated 
in relation to the duration of the study and the preferred and usual lifestyle of the 
participant.  
* Acceptable  barrier  methods  to be used concomitantly  with options  6 or 7 for  the study 
include any of the following:  
• Male or female condom with or without spermicide;  
• Cervical  cap, diaphragm,  or sponge  with spermicide;  
• A combination  of male  condom  with either  cervical  cap, diaphragm,  or sponge 
with spermicide (double -barrier methods).  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  89  
  
 
 
 
 
 
 
 
 
 
 
 
 CCI 
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  90  
 10.6. Appendix  6: Liver  Safety:  Suggested  Actions  and Follow -Up Assessments 
Potential Cases of Drug -Induced Liver Injury  
Humans exposed to a drug who show no sign of liver injury (as determined by  [CONTACT_20023])  are termed  “tolerators,”  while  those  who show  transient  liver injury  but adapt 
are termed “adaptors.” In some participants, transaminase elevations are a harbinger of a 
more serious potential outcome. These participants fail to adapt and therefore are 
“susceptible” to progressive and serious liver injury, commonly referred to as DILI. 
Participants who experience a transaminase elevation above 3 × ULN should be monitored 
more frequently to determine if they are “adaptors” or are “susceptible.”  
In the majority  of DILI  cases,  elevations  in AST  and/or  ALT  precede  T bili elevations 
(>2 × ULN) by [CONTACT_22857]. The increase in T bili typi[INVESTIGATOR_22774]/ALT is/are still elevated above 3 × ULN (ie, AST/ALT and T bili values will be  
elevated  within  the same  laboratory  sample).  In rare instances,  by [CONTACT_29623] T bili elevations 
are detected, AST/ALT values might have decreased. This occurrence is still regarded as a 
potential DILI. Therefore, abnormal elevations  in either AST OR ALT in addition to T bili 
that meet the criteria outlined below are considered potential DILI (assessed per Hy’s law 
criteria) cases and should always be considered important medical events, even before all 
other possible causes of liver injury have been excluded.  
The threshold of laboratory abnormalities for a potential DILI case depends on the 
participant’s  individual  baseline  values  and underlying  conditions.  Participants  who present 
with the following laboratory abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively determine the etiology of the abnormal laboratory values:  
• Participants with AST/ALT and T bili baseline values within the normal range who 
subsequently  present  with AST  OR ALT  values  ≥3 × ULN  AND  a T bili value  ≥2 × ULN 
with no evidence of hemolysis and an alkaline phosphatase value <2 × ULN or not 
available.  
• For participants  with baseline  AST  OR ALT  OR T bili values  above  the ULN,  the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:  
• Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values  ≥2 times  the baseline  values  AND  ≥3 × ULN;  or ≥8 × ULN  (whichever  is 
smaller).  
• Preexisting  values  of T bili above  the normal  range:  T bili level  increased  from 
baseline value by [CONTACT_219911]  ≥1 × ULN or if the value reaches ≥3 × ULN 
(whichever is smaller).  
Rises in AST/ALT and T bili separated by [CONTACT_726] a few weeks should be assessed 
individually  based  on clinical  judgment;  any case where  uncertainty  remains  as to whether  it 
represents a potential Hy’s law case should be reviewed with the sponsor.  
PF-[ADDRESS_1121885] and ALT and T bili for suspected Hy’s law 
cases, additional laboratory tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, total bile acids, and alkaline phosphatase. Consideration should also be given 
to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporaneous analyses at the time of the recognized initial 
abnormalities to determine etiology. A detailed history, including relevant information, such 
as review of ethanol, acetaminophen/paracetamol (either by [CONTACT_20025] a coformulated 
product in prescription or over -the-counter medications), recreational drug, or supplement 
(herbal)  use and consumption,  family  history,  sexual  history,  travel  history,  history  of contact 
[CONTACT_4490] a jaundiced person, surgery, blood transfusion, history of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis  A, B, C, D, and E  infection,  liver imaging  (eg, biliary  tract),  and collection  of serum 
samples for acetaminophen/paracetamol drug and/or protein adduct levels may  be warranted.  
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/ALT and 
T bili elevation defined above should be considered potential DILI (Hy’s law) cases if no 
other  reason  for the LFT abnormalities  has yet  been  found.  Such  potential  DILI  (Hy’s  law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.  
A potential DILI (Hy’s law) case becomes a confirmed case only after all results of 
reasonable  investigations  have  been  received  and have  excluded  an alternative  etiology.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  92  
 10.7. Appendix  7: Kidney  Safety:  Monitoring  Guidelines  
10.7.1.  Laboratory  Assessment  of Change  in Kidney  Function  and Detection  of Kidney 
Injury  
Standard kidney safety monitoring requires assessment of baseline and postbaseline serum 
creatinine (Scr measurement to estimate glomerular filtration rate [Scr -based eGFR] or 
creatinine clearance [eCrCl]). Baseline and postbaseline serum Scys makes it feasible to 
distinguish  AKI from  other  causes  of Scr increase.  If Scr increase  is confirmed  after baseline, 
then reflex measurement of Scys is indicated to estimate the combined Scr -Scys eGFR 
calculation (for adults only).  
Regardless of whether kidney function monitoring tests are required as a routine safety 
monitoring  procedure  in the study,  if the investigator  or sponsor  deems  it necessary  to further 
assess kidney safety and quantify kidney function, then these test results should be managed 
and followed per standard of care.  
10.7.2.  Age-Specific  Kidney  Function  Calculation  Recommendations  
[IP_ADDRESS].  Adults  (18 Years  and Above) —2021  CKD -EPI [INVESTIGATOR_185560]  
 
2021  CKD - 
EPI 
[INVESTIGATOR_811030] 
(mg/dL)  Scys 
(mg/L)  Recommended  eGFR  Equation  
Female  if ≤ 0.7 N/A eGFR  = 143  × (Scr/0.7)-0.241 × (0.9938)Age 
Female  if > 0.7 N/A eGFR  = 143  × (Scr/0.7)-1.200 × (0.9938)Age 
Male  if ≤ 0.9 N/A eGFR  = 142  × (Scr/0.9)-0.302 × (0.9938)Age 
Male  if > 0.9 N/A eGFR  = 142  × (Scr/0.9)-1.200 × (0.9938)Age 
2021  CKD - 
EPI 
[INVESTIGATOR_185572]-Scys 
Combined  Scr 
(mg/dL)  Scys 
(mg/L)  Recommended  eGFR  Equation  
Female  if ≤ 0.7 if ≤ 0.8 eGFR  = 130 × (Scr/0.7)-0.219 × (Scys/0.8)-0.323 × (0.9961)Age 
Female  if ≤ 0.7 if > 0.8 eGFR  = 130 × (Scr/0.7)-0.219 × (Scys/0.8)-0.778 × (0.9961)Age 
Female  if > 0.7 if ≤ 0.8 eGFR  = 130 × (Scr/0.7)-0.544 × (Scys/0.8)-0.323 × (0.9961)Age 
Female  if > 0.7 if > 0.8 eGFR  = 130 × (Scr/0.7)-0.544 × (Scys/0.8)-0.778 × (0.9961)Age 
Male  if ≤ 0.9 if ≤ 0.8 eGFR  = 135 × (Scr/0.9)-0.144 × (Scys/0.8)-0.323 × (0.9961)Age 
Male  if ≤ 0.9 if > 0.8 eGFR  = 135 × (Scr/0.9)-0.144 × (Scys/0.8)-0.778 × (0.9961)Age 
Male  if > 0.9 if ≤ 0.8 eGFR  = 135 ×  (Scr/0.9)-0.544 × (Scys/0.8)-0.323 × (0.9961)Age 
Male  if > 0.9 if > 0.8 eGFR  = 135 ×  (Scr/0.9)-0.544 × (Scys/0.8)-0.778 × (0.9961)Age 
Inker  LA et al. N  Engl J Med. 2021;385:1737 -49.3 
10.7.3.  Adverse  Event  Grading  for Kidney  Safety  Laboratory  Abnormalities  
AE grading  for decline  in kidney  function  (ie, eGFR  or eCrCl)  will be according  to CTCAE 
criteria.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  93  
 10.8. Appendix  8: ECG  Findings  of Potential  Clinical  Concern  
 
ECG  Findings That  May  Qualify  as AEs 
• Marked  sinus  bradycardia  (rate <40 bpm)  lasting  minutes.  
• New  PR interval  prolongation >280 ms. 
• New prolongation of QTcF to >480 ms (absolute) or by  ≥60 ms from baseline.  
• New -onset  atrial  flutter  or fibrillation,  with controlled  ventricular  response  rate: ie, 
rate <120 bpm.  
• New -onset  type I second -degree  (Wenckebach)  AV block  of >30 seconds’ 
duration.  
• Frequent  PVCs,  triplets,  or short  intervals  (<30  seconds)  of consecutive  ventricular 
complexes.  
ECG  Findings That  May  Qualify  as SAEs  
• New  ST-T changes  suggestive  of myocardial  ischemia.  
• New -onset  LBBB  (QRS  complex>120  ms). 
• New -onset  right  bundle  branch  block  (QRS  complex>120  ms). 
• Symptomatic  bradycardia.  
• Asystole:  
• In awake,  symptom -free participants  in sinus  rhythm,  with documented  periods 
of asystole  ≥3.0 seconds  or any escape  rate <40 bpm,  or with an escape  rhythm 
that is below the AV node.  
• In awake,  symptom -free participants  with atrial  fibrillation  and bradycardia 
with [ADDRESS_1121886] 5 seconds or longer.  
• Atrial  flutter  or fibrillation,  with rapid  ventricular  response  rate: rapid  = rate 
>120  bpm.  
• Sustained  supraventricular  tachycardia  (rate >120  bpm)  (“sustained”  = short 
duration with relevant symptoms or lasting >1 minute).  
• Ventricular  rhythms  >30 seconds’  duration,  including  idioventricular  rhythm  (HR 
<40 bpm),  accelerated  idioventricular  rhythm  (HR >40 bpm to <100  bpm),  and 
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  94  
  
monomorphic/polymorphic  ventricular  tachycardia  (HR >100  bpm [such  as 
torsades de pointes]).  
• Type II  second -degree  (Mobitz II)  AV block.  
• Complete  (third -degree)  heart  block.  
ECG  Findings That  Qualify as  SAEs  
• QTcF  prolongation  >500 ms  or > 60 ms  from baseline  
• Change  in pattern  suggestive  of new myocardial  infarction.  
• Sustained  ventricular  tachyarrhythmias  (>30  seconds’  duration).  
• Second - or third -degree  AV block  requiring  pacemaker  placement.  
• Asystolic  pauses  requiring  pacemaker  placement.  
• Atrial flutter or fibrillation with rapid ventricular response  requiring cardioversion.  
• Ventricular  fibrillation/flutter.  
• At the discretion  of the investigator,  any arrhythmia  classified  as an adverse 
experience.  
The enumerated list of major events of potential clinical concern are recommended as “alerts” or 
notifications  from  the core ECG  laboratory  to the investigator  and [COMPANY_007]  study  team,  and not to be 
considered as all -inclusive of what to be reported as AEs/SAEs.  
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  95  
 10.9. Appendix  9: Abbreviations  
The following is a list of abbreviations that may  be used in the protocol.  
 
Abbreviation  Term  
%CV  coefficient  of variation  
Abs absolute  
ADL  activity/activities  of daily  living  
AE adverse  event  
AESI  adverse  event of  special interest  
AKI acute kidney  injury  
ALT  alanine aminotransferase  
API [INVESTIGATOR_811031] -time curve  
AUC last area under  the concentration -time curve  from  [ADDRESS_1121887] quantifiable concentration  
 CCI     
CLp plasma  clearance  
Cmax maximum  observed  concentration  
CO 2 carbon  dioxide  (bicarbonate)  
COVID -[ADDRESS_1121888] 
ECG  electrocardiogram or electrocardiography  
eCrCl  estimated  creatinine  clearance  
eCRF  electronic case report form  
EDB  exposure during breastfeeding  
E-DMC  External  Data  Monitoring  Committee  
EDP exposure during pregnancy  
eGFR  estimated  glomerular  filtration  rate 
ERCP  Endoscopic  retrograde·cholangiao -pancreatography  
eSAE  electrionic  serious  adverse  event  
EU European  Union  
EudraCT  European  Union  Drug  Regulating  Authorities  Clincal  Trials 
(European Clinical Trials Database)  
FDA  Food and Drug Administration  
FIH first-in-human  
FIP first-in-patient  
FL follicular  lymphoma  
FSH follicle -stimulating  hormone  
F/U follow -up 
fu unbound  fractions  
GCP  Good  Clinical  Practice  
GI gastrointestinal  
GLP Good Laboratory  Practice  
GGT  gamma -glutamyl  transferase  
PF-[ADDRESS_1121889]  non-severly  toxic  dose 
HR heart  rate 
HRT  hormone  replacement  therapy  
IB Investigator’s  Brochure  
ICD informed  consent  document  
ICH International  Council  for Harmonisation  of Technical  Requirements 
for Pharmaceuticals for Human Use  
ID identification  
IND Investigational  New  Drug  
INR international  normalized  ratio 
IP Investigational  Product  
IPAL  Investigational Product Accountability  Log 
IPM investigational  product  manual  
IQMP  Integrated quality  management plan 
IRB Institutional  Review  Board  
IV intravenous(ly)  
kel terminal  phase  rate constant  
LBBB  left bundle  branch  block  
LFT liver function  test 
LLN  lower  limit  of normal  
Log e natural  logarithm  
MATE  multidrug and toxin extrusion  
MATE2K  multidrug and toxin extrusion protein [ADDRESS_1121890]  organic  cation  transporter  
PAD  pharmacologic  active  dose 
PCRU  [COMPANY_007] Clinical Research Unit 
PD pharmacodynamic(s)  
P-gp p-glycoprotein  
PI [INVESTIGATOR_63168](s)  
PO Oral 
PR pulse  rate 
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  98  
  
Abbreviation  Term  
PRC2  polycomb  repressive  complex  2 
PSSA  [COMPANY_007]'s Serious Adverse Event Submission  Assistant  
PT prothrombin time 
PTT Partial  thromboplastin  time 
PVC  premature  ventricular  contraction/complex  
QA Quality  assess  
QC Quality  control  
QD Once  a day 
QTc corrected  QT interval  
QTcF  QTc corrected  using  Fridericia’s  formula  
qual qualitative  
rBA relative Bioavailability  
RBC  red blood  cell 
 CCI     
RR respi[INVESTIGATOR_811032] -CoV-[ADDRESS_1121891] bili total bilirubin  
TEAE  Treatment -emergent  adverse  event  
THC  tetrahydrocannabinol  
Tmax time to reach  Cmax 
UACR  urine albumin/creatinine ratio 
UGT  Uridine  diphosphate  glycosyltransferase  
ULN  upper  limit  of normal  
US United  States  
UTI urinary  tract infection  
UVA  ultraviolet A 
UVB  ultraviolet B 
Vss volume  of distribution  at steady -state 
 CCI     
   
WBC  white  blood  cell 
 CCI     
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  99  
  
Abbreviation  Term  
WOCBP  woman/women  of childbearing  potential  
WT Wild type 
PF-06821497  
Protocol  C2321005  
Final  Protocol,  02 Feb 2023  
PFIZER  CONFIDENTIAL  
Page  100  
 11. REFERENCES  
1. O’Carroll  D, Erhardt  S, Pagani  M, et al. The polycomb -group  gene  Ezh2  is required  for 
early mouse development. Mol Cel Biol. 2001;21(13):[ADDRESS_1121892],  and Gastric  pH-Dependent  Drug Interactions.  AAPS  J. 2022;24(16).  DOI: 
10.1208/s12248 -021-[ZIP_CODE] -w. 
3. Inker LA, Eneanya ND, Coresh J, et al. New Creatinine - and Cystatin C -Based 
Equations  to Estimate  GFR  without  Race.  N Engl  J Med.  2021;385(19):1737 -49. 